Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease.
- Authors
- Kriks, Sonja; Shim, Jae-Won; Piao, Jinghua; Ganat, Yosif M; Wakeman, Dustin R; Xie, Zhong; Carrillo-Reid, Luis; Auyeung, Gordon; Antonacci, Chris; Buch, Amanda; Yang, Lichuan; Beal, M Flint; Surmeier, D James; Kordower, Jeffrey H; Tabar, Viviane; Studer, Lorenz
- Year
- 2011
- Journal
- Nature
- PMID
- 22056989
- DOI
- 10.1038/nature10648
- PMCID
- PMC3245796
Human pluripotent stem cells (PSCs) are a promising source of cells for applications in regenerative medicine. Directed differentiation of PSCs into specialized cells such as spinal motoneurons or midbrain dopamine (DA) neurons has been achieved. However, the effective use of PSCs for cell therapy has lagged behind. Whereas mouse PSC-derived DA neurons have shown efficacy in models of Parkinson's disease, DA neurons from human PSCs generally show poor in vivo performance. There are also considerable safety concerns for PSCs related to their potential for teratoma formation or neural overgrowth. Here we present a novel floor-plate-based strategy for the derivation of human DA neurons that efficiently engraft in vivo, suggesting that past failures were due to incomplete specification rather than a specific vulnerability of the cells. Midbrain floor-plate precursors are derived from PSCs 11 days after exposure to small molecule activators of sonic hedgehog (SHH) and canonical WNT signalling. Engraftable midbrain DA neurons are obtained by day 25 and can be maintained in vitro for several months. Extensive molecular profiling, biochemical and electrophysiological data define developmental progression and confirm identity of PSC-derived midbrain DA neurons. In vivo survival and function is demonstrated in Parkinson's disease models using three host species. Long-term engraftment in 6-hydroxy-dopamine-lesioned mice and rats demonstrates robust survival of midbrain DA neurons derived from human embryonic stem (ES) cells, complete restoration of amphetamine-induced rotation behaviour and improvements in tests of forelimb use and akinesia. Finally, scalability is demonstrated by transplantation into parkinsonian monkeys. Excellent DA neuron survival, function and lack of neural overgrowth in the three animal models indicate promise for the development of cell-based therapies in Parkinson's disease.
Induction and neurogenic conversion of hESC-derived midbrain FP precursors is dependent on CHIR99021 additiona) Immunocytochemistry at day 11 for FOXA2 (red), NESTIN (green, upper panels), LMX1A (green, middle panels) and OTX2 (green, lower panels). b,c) Quantification of the data presented in (a); mean Β± SEM, n=3 (independent experiments): *** p < 0.001; ** p < 0.01; p < 0.05 (compared to LSB, Dunnett test). d) Diagram of culture conditions. e,f) Selected lists of differentially expressed transcripts at day 11 comparing LSB/S/F8/CHIR versus LSB (e) or versus LSB/S/F8 (f). g,h) Temporal gene expression analysis for markers of midbrain DA precursor (g), forebrain and ventral non-DA precursor identity (h). Scale bars: 50 ΞΌm.
Immunocytochemical and molecular analysis of midbrain DA neuron fate in LSB/S/F8/CHIR treated versus LSB/S/F8 (hypothalamic) and forebrain LSB (dorsal forebrain) fates.a) Immunocytochemistry at day 25 for co-expression of FOXA2 (blue) with Tuj1(red)/LMX1A(green) (upper panels) and NURR1(red)/TH(green) (lower panels). b) Quantitative co-expression analysis for LSB/S/F8/CHIR; mean Β± SEM, n=3 (independent experiments). c,d) Global gene expression analysis at day 25 (triplicates each). Selected lists of differentially expressed transcripts comparing day 13 versus day 25 in LSB/S/F8/CHIR (c) LSB/S/F8/CHIR versus LSB (d, left panel) and LSB/S/F8 (d, right panel). e) Gene expression analysis for key midbrain DA neuron markers. Significance compared to LSB: Dunnett test: *** p < 0.001; ** p < 0.01; * p < 0.05). Scale bars: 50 ΞΌm.
In vitro maturation and functional characterization of FP versus rosette-derived midbrain DA neuronsa) Immunocytochemistry at day 50 for TH (red), with LMX1A (green) and FOXA2 (blue; left panels) and NURR1 (green, right panels). b) Quantification of TH+, FOXA2+, LMX1+ and NURR1+ cells in rosette- versus FP-derived (LSB/S/F8/CHIR) cultures. c) Quantification of serotonin+ (5-HT), and GABA+ neuronal subtypes at day 50 in rosette-versus FP-derived cultures. d,e) HPLC analysis for DA and metabolites d) Representative HPLC chromatogram in a sample of FP-derived cultures. e) Levels of DA, DOPAC and HVA in FP-and rosette-derived cultures. f) Immunocytochemistry in FP-derived cultures (day 80) for TH (red) and synapsin (green). g-i) Electrophysiological analyses of FP cultures at day 80. Phase contrast image of a patched neuron (g) and corresponding recordings (h). i) Power analysis showing membrane potential oscillations characteristic of DA neuron identity (2~5Hz) Mean Β± SEM; significance (panels b, c, e) comparing FP versus rosette-derived cultures: Studentβs T-test: *** p < 0.001; ** p < 0.01; p < 0.05). Scale bars: 50 ΞΌm in (a), 20 ΞΌm in (f, upper panel), 5 ΞΌm in (f, lower panel) and 20 ΞΌm in (g)
In vivo survival and function of FP-derived human DA neurons in mouse, rat and monkey PD hostsa-d) 6-OHDA lesioned adult mice (NOD-SCID IL2Rgc null strain): a) TH expression and graft morphology at 4.5 months after transplantation. b) Expression of human specific marker (hNCAM, blue), TH (green), and FOXA2 (red). c) Quantification of FOXA2+ and TH+ cells in FP-derived grafts (mean Β± SEM, n=4 at 4.5 months post grafting). d) Amphetamine-induced rotation analysis in FP- (blue) versus rosette-derived (green) grafts. Scale bars: 500 ΞΌm in (a), and 100 and 40 ΞΌm in (b).e-p) 6-OHDA lesioned adult rats: Immunohistochemistry for TH (green) and human specific markers (red) hNA (e) and hNCAM (f). g) Stereological quantification of hNA+, TH+ and TH+ cells co-expressing FOXA2 (average graft volume = 2.6 Β± 0.6 mm3). h-j) Co-expression of TH (green) with FOXA2, PITX3 and NURR1 (red). k-m) Behavioral analysis in FP- versus sham-grafted animals. k) Amphetamine-induced rotational asymmetry. l) stepping test: measuring forelimb akinesia in affected versus non-affected side. m) Cylinder test: measuring ipsi- versus contra-lateral paw preference. Grafted animals showed significant improvement in all three tests (p < 0.01 at 4.5β5 month; n=4β6 each). n-p) Immunohistochemistry for TH (green) and co-expression (red) with DAT (n), GIRK2 (o) and calbindin (p). Significance levels (panels d, k, l, m): ** p < 0.01; p < 0.05). Scale bars: 200 ΞΌm in (e), 50 ΞΌm in (f), 20 ΞΌm in (h-j) and 40 ΞΌm in (n-p).q-t) Adult MPTP lesioned rhesus monkeys. q) Representative graft at 1 month after transplantation expressing human specific cytoplasm marker SC-121 (green). r) TH expression in graft with surrounding TH+ fibers (arrows). s) Co-expression of SC-121 (red) and TH (green). t) Co-expression of FOXA2 (red) and TH+ (green). Scale bars: 2mm for (q), 500 ΞΌm for (r), 200 ΞΌm for (s), and 50 ΞΌm for (t).
| # | Section | Preview |
|---|---|---|
| 0 | Methods Summary | Human ESC (H9, H1) and iPSC lines (2C6 and SeV6) were subjected to a modified dual SMAD-inhibition13β¦ |
| 1 | Methods Summary | à 103 cells in rats) and a total of 7.5 à 106 cells (distributed in 6 tracts; 3 on each side of⦠|
| Name | Type |
|---|---|
| 2C6 local | cohort |
| 6-hydroxydopamine | drug |
| AA | cohort |
| adult NOD-SCID IL2Rgc mice local | cohort |
| adult rhesus monkeys local | cohort |
| amphetamine | drug |
| Bdnf | gene |
| CHIR99021 | drug |
| Cylinder test local | phenotype |
| DA | drug |
| dbcAMP local | drug |
| FGF8 local | drug |
| Focal akinesia local | phenotype |
| Forelimb use local | phenotype |
| GDNF | drug |
| H1 local | cohort |
| H9 local | cohort |
| hemiparkinsonian local | phenotype |
| mice | cohort |
| midbrain | anatomy |
| monkeys | cohort |
| MPTP | drug |
| purmorphamine | drug |
| rats | cohort |
| Rotational analysis local | phenotype |
| SeV6 local | cohort |
| Shh | gene |
| Sprague-Dawley rats | cohort |
| Stepping test local | phenotype |
| striatum | anatomy |
| TGFΞ²3 local | drug |
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Alternative Translation Initiation in PRKN Delays the Onset of Parkinson's Disease and Offers a Therapeutic Target. | Hach A et al. | β | 2026 | β |
| A new dawn for Parkinson's disease: commentary on the emergence of stem cell-based therapies. | Elvira R et al. | β | 2026 | β |
| Bioenergetic and protein processing imbalances in iPSC-dopamine neurons from individuals with idiopathic Parkinson's disease. | Bernard K et al. | β | 2026 | β |
| Biopreservation of a tissue engineered nigrostriatal pathway for tract reconstruction in Parkinson's disease. | Chouhan D et al. | β | 2026 | β |
| Differentiation of human iPSCs into dopaminergic neurons: comparative analysis of 2D and 3D protocols for disease modeling and pharmacology. | Marcotto GS et al. | β | 2026 | β |
| IFNΞ³ alters the aberrant phenotype of Ξ±-synuclein-treated microglia reducing the detrimental impact of their secretome on dopaminergic neurons. | Niskanen J et al. | β | 2026 | β |
| Induced Pluripotent Stem Cells (iPSCs) as a Regenerative Strategy for Parkinson's Disease: Opportunities and Challenges. | Faried A et al. | β | 2026 | β |
| Investigating the efficacy, methods, and challenges of induced pluripotent stem cells (iPSC) therapy in Parkinson's disease. | Mustafa MA et al. | β | 2026 | β |
| miR-214-3p exacerbates mitochondrial dysfunction in parkinson's disease: a multi-omics and mechanistic study. | Wang X et al. | β | 2026 | β |
| Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome. | Mao C et al. | β | 2026 | β |
| Therapeutic Effects of Noninvasive Electrical Stimulation in Combination Transplantation of Human Adipose-Derived Stem Cells-Derived Dopaminergic Neuron on the Monkey Model of Parkinson's Disease. | Huang C et al. | β | 2026 | β |
| The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease. | Barker RA et al. | β | 2026 | β |
| VMAT2 dysfunction impairs vesicular dopamine uptake, driving its oxidation and Ξ±-synuclein pathology in DJ-1-linked Parkinson's neurons. | Heger LM et al. | β | 2026 | β |
| 3D-generation of high-purity midbrain dopaminergic progenitors and lineage-guided refinement of grafts supports Parkinson's disease cell therapy. | Zhang X et al. | β | 2025 | β |
| Activation of endogenous PRKN by structural derepression is linked to increased turnover of the E3 ubiquitin ligase. | Fiesel FC et al. | β | 2025 | β |
| Advances, challenges, and opportunities of human midbrain organoids for modelling of the dopaminergic system. | Fiorenzano A et al. | β | 2025 | β |
| Advantages and challenges of using allogeneic vs. autologous sources for neuronal cell replacement in Parkinson's disease: Insights from non-human primate studies. | Emborg ME et al. | β | 2025 | β |
| A high-fidelity microfluidic platform reveals retrograde propagation as the main mechanism of Ξ±-Synuclein spread in human neurons. | Vroman R et al. | β | 2025 | β |
| Are oligodendrocytes bystanders or drivers of Parkinson's disease pathology? | Salazar Campos JM et al. | β | 2025 | β |
| A systematic review of progenitor survival and maturation in Parkinsonian models. | Comini G et al. | β | 2025 | β |
| Autophagy controls neuronal differentiation by regulating the WNT-DVL signaling pathway. | Vidyawan V et al. | β | 2025 | β |
| BrainSTEM: A single-cell multiresolution fetal brain atlas reveals transcriptomic fidelity of human midbrain cultures. | Toh HSY et al. | β | 2025 | β |
| Cell-based regenerative and rejuvenation strategies for treating neurodegenerative diseases. | Deng S et al. | β | 2025 | β |
| Cell fate acquisition and reprogramming by the proneural transcription factor ASCL1. | Lundie-Brown J et al. | β | 2025 | β |
| Chimeric brain models: Unlocking insights into human neural development, aging, diseases, and cell therapies. | Papetti AV et al. | β | 2025 | β |
| Clinical perspective on pluripotent stem cells derived cell therapies for the treatment of neurodegenerative diseases. | Izrael M et al. | β | 2025 | β |
| Commander complex regulates lysosomal function and is implicated in Parkinson's disease risk. | Minakaki G et al. | β | 2025 | β |
| Compensatory synaptotagmin-11 expression conceals parkinson's disease-like phenotypes in parkin knockout mice. | Dong N et al. | β | 2025 | β |
| Convention vs. innovation III: The promise of stem cell therapy in Parkinson's disease remains bright. | Fasano A et al. | β | 2025 | β |
| Current Applications of Human Pluripotent Stem Cells in Neuroscience Research and Cell Transplantation Therapy for Neurological Disorders. | Verma I et al. | β | 2025 | β |
| Current therapeutic strategies in Parkinson's disease: Future perspectives. | Kim TY et al. | β | 2025 | β |
| Design and green synthesis of carbon Dots/Gold nanoparticles Composites and their applications for neurotransmitters sensing based on emission Spectroscopy. | El-Said WA et al. | β | 2025 | β |
| Differences in neuronal ciliation rate and ciliary content revealed by systematic imaging-based analysis of hiPSC-derived models across protocols. | Haenseler W et al. | β | 2025 | β |
| Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation. | Mahul-Mellier AL et al. | β | 2025 | β |
| Dopamine Cell-Based Replacement Therapies. | Kayhanian S et al. | β | 2025 | β |
| Dopaminergic Axon Tracts Within a Hyaluronic Acid Hydrogel Encasement to Restore the Nigrostriatal Pathway. | GordiΓ‘n-VΓ©lez WJ et al. | β | 2025 | β |
| Dual SMAD inhibitionΒ as a versatile platform in human pluripotent stem cell-based regenerative medicine and disease modeling. | Puspita L et al. | β | 2025 | β |
| Dysregulation of glutamatergic and GABAergic neurons in Treatment-Resistant Depression: Insights from patient-derived neurons. | Tomasoni Z et al. | β | 2025 | β |
| Dysregulation of mitochondrial Ξ±-ketoglutarate dehydrogenase leads to elevated lipid peroxidation in CHCHD2-linked Parkinson's disease models. | Gao G et al. | β | 2025 | β |
| Electrophysiological characterisation of intranigral-grafted hiPSC-derived dopaminergic neurons in a mouse model of Parkinson's disease. | Ballion B et al. | β | 2025 | β |
| Elimination of tumorigenic pluripotent stem cells from their differentiated cell therapy products: An important step toward ensuring safe cell therapy. | Movahed AY et al. | β | 2025 | β |
| Encapsulation of trabecular meshwork mesenchymal stem cell using microfluidic system for differentiation into neuron-like cells. | Rahmani S et al. | β | 2025 | β |
| Engineering fibroblast with reprogramming and spheronization for bone defect repair. | Li Y et al. | β | 2025 | β |
| Established and emerging new approach methodologies in neuroscience. | Imberechts D et al. | β | 2025 | β |
| Exercise your graft - An important lesson for cell replacement therapy for Parkinson's disease. | Daadi MM et al. | β | 2025 | β |
| Exploring the landscape of Parkinson's disease transcriptomics: a quantitative review of research progress and future directions. | Wang Y et al. | β | 2025 | β |
| G6PD deficiency triggers dopamine loss and the initiation of Parkinson's disease pathogenesis. | Stykel MG et al. | β | 2025 | β |
| Generation of Neural Organoids and Their Application in Disease Modeling and Regenerative Medicine. | Huang R et al. | β | 2025 | β |
| Histone bivalency in CNS development. | MΓ€tlik K et al. | β | 2025 | β |
| Human-Induced Pluripotent Stem Cells (iPSCs) for Disease Modeling and Insulin Target Cell Regeneration in the Treatment of Insulin Resistance: A Review. | Thiab S et al. | β | 2025 | β |
| Human Pluripotent Stem Cell-Based Therapies for Parkinson's Disease: Challenges and Potential Solutions. | Chang MY et al. | β | 2025 | β |
| Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors. | Yan W et al. | β | 2025 | β |
| Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease. | Eubanks E et al. | β | 2025 | β |
| Induced Neural Progenitor Specification from Human Pluripotent Stem Cells by a Refined Synthetic Notch Platform. | Hamann CA et al. | β | 2025 | β |
| Induced pluripotent stem cell-related approaches to generate dopaminergic neurons for Parkinson's disease. | Yi LX et al. | β | 2025 | β |
| Inhibition or genetic reduction of ASAH1/acid ceramidase restore Ξ±-synuclein clearance in mutant GBA1 dopamine neurons from Parkinson's patients. | Kumar M et al. | β | 2025 | β |
| Investigating the ageing-Parkinson's disease nexus: standardisation of in vitro models and techniques by the PD-AGE network. | Bury AG et al. | β | 2025 | β |
| iPSC-based cell replacement therapy: from basic research to clinical application. | Takahashi J | β | 2025 | β |
| Lewy pathology formation in patient-derived GBA1 Parkinson's disease midbrain organoids. | Frattini E et al. | β | 2025 | β |
| Linear ubiquitination at damaged lysosomes induces local NFKB activation and controls cell survival. | Zein L et al. | β | 2025 | β |
| Long-Term Engraftment of Cryopreserved Human Neurons for In Vivo Disease Modeling in Neurodegenerative Disease. | Marmion DJ et al. | β | 2025 | β |
| LRRK2-Mediated Neuroinflammation-Induced Neuronal Dysfunctions in a Parkinson's and Alzheimer's Disease Cellular Model. | Mutti V et al. | β | 2025 | β |
| LRRK2-mutant microglia and neuromelanin synergize to drive dopaminergic neurodegeneration in an iPSC-based Parkinson's disease model. | Blasco-Agell L et al. | β | 2025 | β |
| Lysosomal TPC2 channels disrupt Ca2+ entry and dopaminergic function in models of LRRK2-Parkinson's disease. | Gregori M et al. | β | 2025 | β |
| Midline assembloids reveal regulators of human axon guidance. | Onesto MM et al. | β | 2025 | β |
| Molecular Determinants of A9 Dopaminergic Neurons. | Mishra AK et al. | β | 2025 | β |
| MorPhiC Consortium: towards functional characterization of all human genes. | Adli M et al. | β | 2025 | β |
| Morphological profiling reveals neuroprotection via mitochondrial uncoupling in human dopaminergic neurons. | Gorgogietas V et al. | β | 2025 | β |
| Nanoelectrode-Mediated Extracellular Electrical Stimulation Directing Dopaminergic Neuronal Differentiation of Stem Cells for Improved Parkinson's Disease Therapy. | Wang L et al. | β | 2025 | β |
| Nanosensor-based imaging of realtime dopamine release in neurons derived from iPSCs of patients with Parkinson's disease. | Lee N et al. | β | 2025 | β |
| Neural stem cells of the subventricular zone: A potential stem cell pool for brain repair in Parkinson's disease. | Verkerke M et al. | β | 2025 | β |
| Patient-Derived Neurons Exhibit Ξ±-Synuclein Pathology and Previously Unrecognized Major Histocompatibility Complex Class I Elevation in Mitochondrial Membrane Protein-Associated Neurodegeneration. | Heger LM et al. | β | 2025 | β |
| Phase I trial of hESΒ cell-derived dopaminergic neurons for Parkinson's disease. | Tabar V et al. | β | 2025 | β |
| Polyphenols as Wnt/Ξ²-catenin pathway modulators: A promising strategy in clinical neurodegeneration. | Utpal BK et al. | β | 2025 | β |
| Preparation of human astrocytes with potent therapeutic functions from human pluripotent stem cells using ventral midbrain patterning. | Nam YR et al. | β | 2025 | β |
| Progression of differentiation of iPSCs into specific subtypes of neurons. | Wang J et al. | β | 2025 | β |
| Recombinant cathepsins B and L promote Ξ±-synuclein clearance and restore lysosomal function in human and murine models with Ξ±-synuclein pathology. | Balta D et al. | β | 2025 | β |
| Regenerating Locus Coeruleus-Norepinephrine (LC-NE) Function: A Novel Approach for Neurodegenerative Diseases. | Yang Y et al. | β | 2025 | β |
| SARM1 activation induces reversible mitochondrial dysfunction and can be prevented in human neurons by antisense oligonucleotides. | Loreto A et al. | β | 2025 | β |
| Sex-dependent preventive effects of prenatal N-acetyl-cysteine on neuronal, emotional and metabolic dysfunctions following exposure to maternal high-fat diet in mice. | Musillo C et al. | β | 2025 | β |
| SLC7A11 is an unconventional H<sup>+</sup> transporter in lysosomes. | Zhou N et al. | β | 2025 | β |
| Stem Cell-Based Approaches in Parkinson's Disease Research. | Kim MS et al. | β | 2025 | β |
| Stem cell-derived dopamine cell therapies for Parkinson's disease: what have the first trials shown? | Barker RA et al. | β | 2025 | β |
| Stem Cell Revolutions: An alliance for Parkinson's disease driven by European Commission consortia. | Cattaneo E et al. | β | 2025 | β |
| Stem cells strike back: advancements in Alzheimer's and Parkinson's disease treatment and modeling efforts from 2019 to 2024. | IsakoviΔ J et al. | β | 2025 | β |
| Stem cells therapy in neurodegenerative and neuroimmune diseases: Current status of treatments and future prospects. | Shi M et al. | β | 2025 | β |
| Stem cell therapy: a revolutionary cure or a pandora's box. | Marei HE | β | 2025 | β |
| Stem cell therapy for Parkinson's disease: A new hope for neural regeneration. | Mokhtari YG et al. | β | 2025 | β |
| Supramolecular nanostructure mimics GDNF trophic effects in vitro on human dopaminergic neurons. | Carballo-Molina OA et al. | β | 2025 | β |
| Sustaining Brain Youth by Neural Stem Cells: Physiological and Therapeutic Perspectives. | Santos M et al. | β | 2025 | β |
| Synaptic deregulation of cholinergic projection neurons causes olfactory dysfunction across five fly Parkinsonism models. | Pech U et al. | β | 2025 | β |
| Synaptic vesicle characterization of iPSC-derived dopaminergic neurons provides insight into distinct secretory vesicle pools. | Fujise K et al. | β | 2025 | β |
| Synergy between stem cell therapy and brain-derived neurotrophic factor (BDNF) in Parkinson's disease: a mini-review of combined neuroregenerative strategies. | Jonny J et al. | β | 2025 | β |
| The Effects of PLGA Nanoparticles Containing Different Growth Factors on Neural Stem Cell Differentiation and Their Transition Efficiency After Targeting With TRF. | AΓ§Δ±ksarΔ± A et al. | β | 2025 | β |
| Three-dimensional midbrain organoids: a next-generation tool for Parkinson's disease modelling and drug discovery. | Elvira R et al. | β | 2025 | β |
| Tissue Stem Cell-Based Therapies in Parkinson's Disease: A Scoping Review of Therapeutic Mechanisms and Translational Outcomes. | Cueva E et al. | β | 2025 | β |
| Ultra-sensitive UHPLC-MS/MS method for simultaneous quantification of 31 neurochemicals in zebrafish larvae and brain. | Romero-Alfano I et al. | β | 2025 | β |
| Advances in animal models of Parkinson's disease. | He S et al. | β | 2024 | β |
| Advances in human cellular mechanistic understanding and drug discovery of brain organoids for neurodegenerative diseases. | Lei T et al. | β | 2024 | β |
| Advances in human pluripotent stem cell reporter systems. | Puspita L et al. | β | 2024 | β |
| Advancing Parkinson's disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells. | Clark BJ et al. | β | 2024 | β |
| An epigenetic barrier sets the timing of human neuronal maturation. | Ciceri G et al. | β | 2024 | β |
| An ultra-sensitive platinized nanocavity electrode for analysis of cytosolic catecholamines in one living cell. | Ma Y et al. | β | 2024 | β |
| Assembloid models of cell-cell interaction to study tissue and disease biology. | Onesto MM et al. | β | 2024 | β |
| Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson's model. | Weiss F et al. | β | 2024 | β |
| Autism patient-derived SHANK2B<sup>Y29X</sup> mutation affects the development of ALDH1A1 negative dopamine neuron. | Lai W et al. | β | 2024 | β |
| Autologous vs heterologous cell replacement strategies for Parkinson disease and other neurologic diseases. | Emborg ME et al. | β | 2024 | β |
| Bioreactor-produced iPSCs-derived dopaminergic neuron-containing neural microtissues innervate and normalize rotational bias in a dose-dependent manner in a Parkinson rat model. | Prudon N et al. | β | 2024 | β |
| Can pluripotent/multipotent stem cells reverse Parkinson's disease progression? | Wu Y et al. | β | 2024 | β |
| Cell line specific alterations in genes associated with dopamine metabolism and signaling in midbrain dopaminergic neurons derived from 22q11.2 deletion carriers with elevated dopamine synthesis capacity. | Reid MJ et al. | β | 2024 | β |
| Cell reprogramming therapy for Parkinson's disease. | Dong W et al. | β | 2024 | β |
| Changes in Oxidised Phospholipids in Response to Oxidative Stress in <i>Microtubule-Associated Protein Tau</i> (<i>MAPT</i>) Mutant Dopamine Neurons. | Bradford X et al. | β | 2024 | β |
| Chronic Opioid Treatment Arrests Neurodevelopment and Alters Synaptic Activity in Human Midbrain Organoids. | Kim HS et al. | β | 2024 | β |
| Circuit integration by transplanted human neurons. | Yuan Q et al. | β | 2024 | β |
| Clinical translation of pluripotent stem cell-based therapies: successes and challenges. | Christiansen JR et al. | β | 2024 | β |
| Continuous immunosuppression is required for suppressing immune responses to xenografts in non-human primate brains. | Feng S et al. | β | 2024 | β |
| Cortisol-dependent impairment of dendrite plasticity in human dopaminergic neurons derived from hiPSCs is restored by ketamine: Relevance for major depressive disorders. | Cavalleri L et al. | β | 2024 | β |
| CRISPRi: a way to integrate iPSC-derived neuronal models. | Franks SNJ et al. | β | 2024 | β |
| Deciphering the Pathophysiological Mechanisms Underpinning Myoclonus Dystonia Using Pluripotent Stem Cell-Derived Cellular Models. | Li Z et al. | β | 2024 | β |
| DeePhys: A machine learning-assisted platform for electrophysiological phenotyping of human neuronal networks. | Hornauer P et al. | β | 2024 | β |
| Direct conversion of human umbilical cord mesenchymal stem cells into dopaminergic neurons for Parkinson's disease treatment. | Liu J et al. | β | 2024 | β |
| Disease-specific interventions: The use of cell and gene therapies for Parkinson disease. | Barker RA et al. | β | 2024 | β |
| Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson's disease model. | Morrone Parfitt G et al. | β | 2024 | β |
| Diverting the food-freezing technology improves the cryopreservation efficiency of induced pluripotent stem cells and derived neurospheres. | Bamba K et al. | β | 2024 | β |
| Dopamineβiron homeostasis interaction rescues mitochondrial fitness in Parkinson's disease. | Buoso C et al. | β | 2024 | β |
| Dopaminergic progenitors generated by small molecule approach survived, integrated, and promoted functional recovery in (6-OHDA) mouse model of Parkinson's disease. | Alexanian AR et al. | β | 2024 | β |
| Early deficits in an in vitro striatal microcircuit model carrying the Parkinson's GBA-N370S mutation. | Do QB et al. | β | 2024 | β |
| Elevated parkinsonism pathological markers in dopaminergic neurons with developmental exposure to atrazine. | Zhao H et al. | β | 2024 | β |
| Elevated Ξ±-synuclein levels inhibit mitophagic flux. | Kinnart I et al. | β | 2024 | β |
| Emerging Human Pluripotent Stem Cell-Based Human-Animal Brain Chimeras for Advancing Disease Modeling and Cell Therapy for Neurological Disorders. | Ji Y et al. | β | 2024 | β |
| Engineering regional diversity: A morphogen screen for patterned brain organoids. | Panagiotakos G et al. | β | 2024 | β |
| Exploiting spatiotemporal regulation of FZD5 during neural patterning for efficient ventral midbrain specification. | Yang A et al. | β | 2024 | β |
| Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells. | Tao Y et al. | β | 2024 | β |
| Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy. | Parmasad JA et al. | β | 2024 | β |
| History of cellular grafting for central nervous system repair-A clinical perspective. | Lindvall O | β | 2024 | β |
| Host circuit engagement of human cortical organoids transplanted in rodents. | Kelley KW et al. | β | 2024 | β |
| Human amniotic epithelial stem cell-derived dopaminergic neuron-like cells ameliorate motor dysfunction in a rat model of Parkinson's disease. | Jiang T et al. | β | 2024 | β |
| Human midbrain organoids: a powerful tool for advanced Parkinson's disease modeling and therapy exploration. | Cui X et al. | β | 2024 | β |
| Human stem cell transplantation models of Alzheimer's disease. | Ifediora N et al. | β | 2024 | β |
| Immunosuppression in stem cell clinical trials of neural and retinal cell types: A systematic review. | Gowrishankar S et al. | β | 2024 | β |
| In and out: Benchmarking inΒ vitro, inΒ vivo, exΒ vivo, and xenografting approaches for an integrative brain disease modeling pipeline. | Pereira MF et al. | β | 2024 | β |
| Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase. | Kim MJ et al. | β | 2024 | β |
| Integrating Mitochondrial Biology into Innovative Cell Therapies for Neurodegenerative Diseases. | Ore A et al. | β | 2024 | β |
| Intracellular delivery of Parkin-RING0-based fragments corrects Parkin-induced mitochondrial dysfunction through interaction with SLP-2. | Zanon A et al. | β | 2024 | β |
| Lineage tracing of stem cell-derived dopamine grafts in a Parkinson's model reveals shared origin of all graft-derived cells. | Storm P et al. | β | 2024 | β |
| Mesenchymal Stem Cell-Derived Exosomes as a Neuroregeneration Treatment for Alzheimer's Disease. | Shah S et al. | β | 2024 | β |
| Mitochondrial Calcium Transport During Autophagy Initiation. | Chandra S et al. | β | 2024 | β |
| Modulation of human induced neural stem cell-derived dopaminergic neurons by DREADD reveals therapeutic effects on a mouse model of Parkinson's disease. | Wang X et al. | β | 2024 | β |
| Mouse Ξ±-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases. | Sokratian A et al. | β | 2024 | β |
| Multiple factors to assist human-derived induced pluripotent stem cells to efficiently differentiate into midbrain dopaminergic neurons. | Chen Y et al. | β | 2024 | β |
| Neuronal Vulnerability to Degeneration in Parkinson's Disease and Therapeutic Approaches. | Sharma T et al. | β | 2024 | β |
| Next-generation direct reprogramming. | Keshri R et al. | β | 2024 | β |
| One-step cell biomanufacturing platform: porous gelatin microcarrier beads promote human embryonic stem cell-derived midbrain dopaminergic progenitor cell differentiation <i>in vitro</i> and survival after transplantation <i>in vivo</i>. | Feng L et al. | β | 2024 | β |
| Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons. | Mohd Rafiq N et al. | β | 2024 | β |
| Past, present, and future of cell replacement therapy for parkinson's disease: a novel emphasis on host immune responses. | Park TY et al. | β | 2024 | β |
| Precision Medicine in Parkinson's Disease Using Induced Pluripotent Stem Cells. | Kim MS et al. | β | 2024 | β |
| Recent advances in stem cell therapy: efficacy, ethics, safety concerns, and future directions focusing on neurodegenerative disorders - a review. | Khandia R et al. | β | 2024 | β |
| [Rho kinase inhibitor Y27632 promotes survival of human induced pluripotent stem cells during differentiation into functional midbrain dopaminergic progenitor cells in <i>vitro</i>]. | Li Y et al. | β | 2024 | β |
| Stem Cell Interventions in Neurology: From Bench to Bedside. | Pappolla MA et al. | β | 2024 | β |
| Strategies for modeling aging and age-related diseases. | Jothi D et al. | β | 2024 | β |
| Suppression of ferroptosis by vitamin A or radical-trapping antioxidants is essential for neuronal development. | Tschuck J et al. | β | 2024 | β |
| Survival and maturation of human induced pluripotent stem cell-derived dopaminergic progenitors in the parkinsonian rat brain is enhanced by transplantation in a neurotrophin-enriched hydrogel. | Comini G et al. | β | 2024 | β |
| Synaptic dysfunction and extracellular matrix dysregulation in dopaminergic neurons from sporadic and E326K-GBA1 Parkinson's disease patients. | Rosh I et al. | β | 2024 | β |
| Synaptic Vesicle Glycoprotein 2C: a role in Parkinson's disease. | Chang CH et al. | β | 2024 | β |
| Tagless LysoIP for immunoaffinity enrichment of native lysosomes from clinical samples. | Saarela D et al. | β | 2024 | β |
| TARGET-seq: Linking single-cell transcriptomics of human dopaminergic neurons with their target specificity. | Fiorenzano A et al. | β | 2024 | β |
| Templated Pluripotent Stem Cell Differentiation via Substratum-Guided Artificial Signaling. | Brien HJ et al. | β | 2024 | β |
| The hexosamine biosynthetic pathway rescues lysosomal dysfunction in Parkinson's disease patient iPSC derived midbrain neurons. | Wani WY et al. | β | 2024 | β |
| The history and status of dopamine cell therapies for Parkinson's disease. | Barker RA et al. | β | 2024 | β |
| The Neuroanatomy of Induced Pluripotent Stem Cells: In Vitro Models of Subcortical Nuclei in Neurodegenerative Disorders. | Galgani A et al. | β | 2024 | β |
| TNF-NF-ΞΊB-p53 axis restricts inΒ vivo survival of hPSC-derived dopamine neurons. | Kim TW et al. | β | 2024 | β |
| Transcription Factor-Mediated Generation of Dopaminergic Neurons from Human iPSCs-A Comparison of Methods. | McDonald KO et al. | β | 2024 | β |
| Treating activated regulatory T cells with pramipexole protects human dopaminergic neurons from 6-OHDA-induced degeneration. | Guevara-Salinas A et al. | β | 2024 | β |
| Unravelling the Parkinson's puzzle, from medications and surgery to stem cells and genes: a comprehensive review of current and future management strategies. | Chandrababu K et al. | β | 2024 | β |
| Upregulated ECM genes and increased synaptic activity in Parkinson's human DA neurons with PINK1/ PRKN mutations. | Tripathi U et al. | β | 2024 | β |
| VPS13C regulates phospho-Rab10-mediated lysosomal function in human dopaminergic neurons. | SchrΣ§der LF et al. | β | 2024 | β |
| Ξ±-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson's disease. | Zalon AJ et al. | β | 2024 | β |
| A Balance between Inter- and Intra-Microgel Mechanics Governs Stem Cell Viability in Injectable Dynamic Granular Hydrogels. | Morley CD et al. | β | 2023 | β |
| Acid ceramidase involved in pathogenic cascade leading to accumulation of Ξ±-synuclein in iPSC model of GBA1-associated Parkinson's disease. | Kumar M et al. | β | 2023 | β |
| A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson's disease. | Nakamura R et al. | β | 2023 | β |
| Advanced human iPSC-based preclinical model for Parkinson's disease with optogenetic alpha-synuclein aggregation. | Kim MS et al. | β | 2023 | β |
| Advancing cell therapy for neurodegenerative diseases. | Temple S | β | 2023 | β |
| A loss-of-function mutation in human Oxidation Resistance 1 disrupts the spatial-temporal regulation of histone arginine methylation in neurodevelopment. | Lin X et al. | β | 2023 | β |
| A mitochondrial inside-out iron-calcium signal reveals drug targets for Parkinson's disease. | Bharat V et al. | β | 2023 | β |
| An atlas of lamina-associated chromatin across twelve human cell types reveals an intermediate chromatin subtype. | Shah PP et al. | β | 2023 | β |
| An Efficient 2D Protocol for Differentiation of iPSCs into Mature Postmitotic Dopaminergic Neurons: Application for Modeling Parkinson's Disease. | Lebedeva OS et al. | β | 2023 | β |
| A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides. | Paul KC et al. | β | 2023 | β |
| A protocol for the differentiation of human embryonic stem cells into midbrain dopaminergic neurons. | Nishimura K et al. | β | 2023 | β |
| A review of protocols for brain organoids and applications for disease modeling. | Mayhew CN et al. | β | 2023 | β |
| A Robust Pipeline for the Multi-Stage Accelerated Differentiation of Functional 3D Cortical Organoids from Human Pluripotent Stem Cells. | Whye D et al. | β | 2023 | β |
| Automated high-content imaging in iPSC-derived neuronal progenitors. | Papandreou A et al. | β | 2023 | β |
| Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S <i>GBA</i> Variant Carriers with and without Parkinson's Disease. | Grigor'eva EV et al. | β | 2023 | β |
| Cell Replacement Therapy for Brain Repair: Recent Progress and Remaining Challenges for Treating Parkinson's Disease and Cortical Injury. | Harary PM et al. | β | 2023 | β |
| Challenges in the clinical advancement of cell therapies for Parkinson's disease. | Skidmore S et al. | β | 2023 | β |
| Challenges involved in cell therapy for Parkinson's disease using human pluripotent stem cells. | Moon H et al. | β | 2023 | β |
| Characterization of the pathogenic Ξ±-Synuclein Variant V15A in ParkinsonΒ΄s disease. | Diaw SH et al. | β | 2023 | β |
| Co-transplantation of autologous T<sub>reg</sub> cells in a cell therapy for Parkinson's disease. | Park TY et al. | β | 2023 | β |
| CRISPR-Cas9-Edited SNCA Knockout Human Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons and Their Vulnerability to Neurotoxicity. | Inoue S et al. | β | 2023 | β |
| Cryopreserved clinical-grade human embryonic stem cell-derived dopaminergic progenitors function in Parkinson's disease models. | Naderi S et al. | β | 2023 | β |
| Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson's Disease. | Cha Y et al. | β | 2023 | β |
| Cytokine Profiling in Human iPSC-Derived Dopaminergic Neuronal and Microglial Cultures. | Knappe E et al. | β | 2023 | β |
| Deconvolution of spatial sequencing provides accurate characterization of hESC-derived DA transplants <i>inΒ vivo</i>. | RΓ‘jovΓ‘ J et al. | β | 2023 | β |
| Development of a Method for the In Vivo Generation of Allogeneic Hearts in Chimeric Mouse Embryos. | Founta KM et al. | β | 2023 | β |
| Development, wiring and function of dopamine neuron subtypes. | Garritsen O et al. | β | 2023 | β |
| Differentiation of astrocytes with characteristics of ventral midbrain from human embryonic stem cells. | Yeon GB et al. | β | 2023 | β |
| [Directed differentiation of human induced pluripotent stem cells into midbrain]. | Xu J et al. | β | 2023 | β |
| Directional induction of neural stem cells, a new therapy for neurodegenerative diseases and ischemic stroke. | Nie L et al. | β | 2023 | β |
| Enabling Survival of Transplanted Neural Precursor Cells in the Ischemic Brain. | Wang Z et al. | β | 2023 | β |
| Enhanced production of mesencephalic dopaminergic neurons from lineage-restricted human undifferentiated stem cells. | Maimaitili M et al. | β | 2023 | β |
| Enhancing Our Understanding of Cell Types, Differentiation, and Disease Through Enhancers: An Interview with CΓ©sar Daniel MelΓ©ndez-RamΓrez, MS. | Abu-Shamma R | β | 2023 | β |
| Expression Pattern of Trace Amine-Associated Receptors during Differentiation of Human Pluripotent Stem Cells to Dopaminergic Neurons. | Katolikova NV et al. | β | 2023 | β |
| First-in-human transplantation of autologous induced neural stem cell-derived dopaminergic precursors to treat Parkinson's disease. | Chen Z et al. | β | 2023 | β |
| From 2D to 3D: Development of Monolayer Dopaminergic Neuronal and Midbrain Organoid Cultures for Parkinson's Disease Modeling and Regenerative Therapy. | Yeap YJ et al. | β | 2023 | β |
| From cells to insights: the power of human pluripotent stem cell-derived cortical interneurons in psychiatric disorder modeling. | Ni P et al. | β | 2023 | β |
| From Lysosomal Storage Disorders to Parkinson's Disease - Challenges and Opportunities. | MΓ€chtel R et al. | β | 2023 | β |
| High Yield of Functional Dopamine-like Neurons Obtained in NeuroForsk 2.0 Medium to Study Acute and Chronic Rotenone Effects on Oxidative Stress, Autophagy, and Apoptosis. | Quintero-Espinosa DA et al. | β | 2023 | β |
| Honokiol decreases alpha-synuclein mRNA levels and reveals novel targets for modulating alpha-synuclein expression. | Fagen SJ et al. | β | 2023 | β |
| Human Embryonic Stem Cell-Derived Immature Midbrain Dopaminergic Neurons Transplanted in Parkinsonian Monkeys. | LΓ³pez-Ornelas A et al. | β | 2023 | β |
| Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease. | Zheng X et al. | β | 2023 | β |
| Identifying secreted biomarkers of dopaminergic ventral midbrain progenitor cells. | Rifes P et al. | β | 2023 | β |
| Impaired Autophagic-Lysosomal Fusion in Parkinson's Patient Midbrain Neurons Occurs through Loss of ykt6 and Is Rescued by Farnesyltransferase Inhibition. | Pitcairn C et al. | β | 2023 | β |
| Increased cysteine metabolism in PINK1 models of Parkinson's disease. | Travaglio M et al. | β | 2023 | β |
| Induction of dopaminergic neurons for neuronal subtype-specific modeling of psychiatric disease risk. | Powell SK et al. | β | 2023 | β |
| Involvement of DA D3 Receptors in Structural Neuroplasticity of Selected Limbic Brain Circuits: Possible Role in Treatment-Resistant Depression. | Merlo Pich E et al. | β | 2023 | β |
| [iPS cell technologies toward overcoming neurological diseases]. | Kimura T et al. | β | 2023 | β |
| Lessons learnt, and still to learn, in first in human stem cell trials. | Barker RA et al. | β | 2023 | β |
| Mapping of clonal lineages across developmental stages in human neural differentiation. | You Z et al. | β | 2023 | β |
| Midbrain organoids-development and applications in Parkinson's disease. | Toh HSY et al. | β | 2023 | β |
| Miniature-swine iPSC-derived GABA progenitor cells function in a rat Parkinson's disease model. | Guo Y et al. | β | 2023 | β |
| Mitochondrial and Endoplasmic Reticulum Stress Trigger Triglyceride Accumulation in Models of Parkinson's Disease Independent of Mutations in MAPT. | Fernandes HJR et al. | β | 2023 | β |
| Molecular phenotypes of mitochondrial dysfunction in clinically non-manifesting heterozygous PRKN variant carriers. | Castelo Rueda MP et al. | β | 2023 | β |
| Neurite Outgrowth and Gene Expression Profile Correlate with Efficacy of Human Induced Pluripotent Stem Cell-Derived Dopamine Neuron Grafts. | Hills R et al. | β | 2023 | β |
| Nicotine-mediated effects in neuronal and mouse models of synucleinopathy. | Fares MB et al. | β | 2023 | β |
| Opportunities and limitations for studying neuropsychiatric disorders using patient-derived induced pluripotent stem cells. | Hong Y et al. | β | 2023 | β |
| Organ-Chips Enhance the Maturation of Human iPSC-Derived Dopamine Neurons. | Otero MG et al. | β | 2023 | β |
| Parallel neurodegenerative phenotypes in sporadic Parkinson's disease fibroblasts and midbrain dopamine neurons. | Corenblum MJ et al. | β | 2023 | β |
| Parkin regulates amino acid homeostasis at mitochondria-lysosome (M/L) contact sites in Parkinson's disease. | Peng W et al. | β | 2023 | β |
| Parkinson's disease-linked parkin mutation disrupts recycling of synaptic vesicles in human dopaminergic neurons. | Song P et al. | β | 2023 | β |
| PC3T: a signature-driven predictor of chemical compounds for cellular transition. | Han L et al. | β | 2023 | β |
| Pluripotent Stem Cell-derived Dopaminergic Neurons for Studying Developmental Neurotoxicity. | Kreutz A et al. | β | 2023 | β |
| Polymorphic USP8 allele promotes Parkinson's disease by inducing the accumulation of Ξ±-synuclein through deubiquitination. | Wu S et al. | β | 2023 | β |
| Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson's disease GBA-N370S dopamine neurons. | Bogetofte H et al. | β | 2023 | β |
| Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD. | Kirkeby A et al. | β | 2023 | β |
| Quantitative Proteomics for the Development and Manufacturing of Human-Induced Pluripotent Stem Cell-Derived Neural Stem Cells Using Data-Independent Acquisition Mass Spectrometry. | Urasawa T et al. | β | 2023 | β |
| Reciprocal effects of alpha-synuclein aggregation and lysosomal homeostasis in synucleinopathy models. | Drobny A et al. | β | 2023 | β |
| Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders. | Dutan Polit L et al. | β | 2023 | β |
| Reenacting Neuroectodermal Exposure of Hematopoietic Progenitors Enables Scalable Production of Cryopreservable iPSC-Derived Human Microglia. | Mathews M et al. | β | 2023 | β |
| Restorative cell and gene therapies for Parkinson's disease. | Barker RA et al. | β | 2023 | β |
| ROS-responsive exogenous functional mitochondria can rescue neural cells post-ischemic stroke. | Li Y et al. | β | 2023 | β |
| Sex and Brain: The Role of Sex Chromosomes and Hormones in Brain Development and Parkinson's Disease. | Terrin F et al. | β | 2023 | β |
| Single-Cell Transcriptomics and In Vitro Lineage Tracing Reveals Differential Susceptibility of Human iPSC-Derived Midbrain Dopaminergic Neurons in a Cellular Model of Parkinson's Disease. | Cardo LF et al. | β | 2023 | β |
| Single-cell transcriptomics identifies perturbed molecular pathways in midbrain organoids using Ξ±-synuclein triplication Parkinson's disease patient-derived iPSCs. | Patikas N et al. | β | 2023 | β |
| Single-cell transcriptomics reveals correct developmental dynamics and high-quality midbrain cell types by improved hESC differentiation. | Nishimura K et al. | β | 2023 | β |
| S-Nitrosylation-mediated dysfunction of TCA cycle enzymes in synucleinopathy studied in postmortem human brains and hiPSC-derived neurons. | Doulias PT et al. | β | 2023 | β |
| Stem cell programmingΒ - prospects for perinatal medicine. | Berg LJ et al. | β | 2023 | β |
| TGFΞ²3, dibutyryl cAMP and a notch inhibitor modulate phenotype late in stem cell-derived dopaminergic neuron maturation. | Sibuea S et al. | β | 2023 | β |
| The contribution of inflammatory astrocytes to BBB impairments in a brain-chip model of Parkinson's disease. | de Rus Jacquet A et al. | β | 2023 | β |
| The enhanced generation of motor neurons from mESCs by MgAl layered double hydroxide nanoparticles. | Bai Y et al. | β | 2023 | β |
| The Foundational Data Initiative for Parkinson Disease: Enabling efficient translation from genetic maps to mechanism. | Bressan E et al. | β | 2023 | β |
| Unconventional secretion of Ξ±-synuclein mediated by palmitoylated DNAJC5 oligomers. | Wu S et al. | β | 2023 | β |
| Understanding and modeling nerve-cancer interactions. | Le TT et al. | β | 2023 | β |
| Wnt signaling in stem cells during development and cell lineage specification. | Chidiac R et al. | β | 2023 | β |
| 100 plus years of stem cell research-20 years of ISSCR. | Lendahl U | β | 2022 | β |
| A chemically-defined plastic scaffold for the xeno-free production of human pluripotent stem cells. | Shimizu E et al. | β | 2022 | β |
| A Dynamic 3D Aggregate-Based System for the Successful Expansion and Neural Induction of Human Pluripotent Stem Cells. | Miranda CC et al. | β | 2022 | β |
| A novel two-factor monosynaptic TRIO tracing method for assessment of circuit integration of hESC-derived dopamine transplants. | Aldrin-Kirk P et al. | β | 2022 | β |
| Application and prospects of high-throughput screening for <i>in vitro</i> neurogenesis. | Zhang SY et al. | β | 2022 | β |
| Application of stem cell biology in treating neurodegenerative diseases. | Jia N et al. | β | 2022 | β |
| Approaches for corneal endothelium regenerative medicine. | CatalΓ P et al. | β | 2022 | β |
| A reference human induced pluripotent stem cell line for large-scale collaborative studies. | Pantazis CB et al. | β | 2022 | β |
| A scalable and tunable thermoreversible polymer for 3D human pluripotent stem cell biomanufacturing. | Johnson HJ et al. | β | 2022 | β |
| Automated measurement of fluorescence signals reveals a significant increase of the graft-derived neurite extension in neonates compared to aged rats. | Grinand L et al. | β | 2022 | β |
| Axonal Tract Reconstruction Using a Tissue-Engineered Nigrostriatal Pathway in a Rat Model of Parkinson's Disease. | Struzyna LA et al. | β | 2022 | β |
| Biomaterial and tissue-engineering strategies for the treatment of brain neurodegeneration. | Martinez B et al. | β | 2022 | β |
| Brain Regional Identity and Cell Type Specificity Landscape of Human Cortical Organoid Models. | Magni M et al. | β | 2022 | β |
| Ceramide and Sphingosine-1-Phosphate in Neurodegenerative Disorders and Their Potential Involvement in Therapy. | Tringali C et al. | β | 2022 | β |
| Combining NGN2 programming and dopaminergic patterning for a rapid and efficient generation of hiPSC-derived midbrain neurons. | Sheta R et al. | β | 2022 | β |
| Comparative efficacy of surgical approaches to disease modification in Parkinson disease. | Rahimpour S et al. | β | 2022 | β |
| CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease. | Rahman MU et al. | β | 2022 | β |
| "Cutting the Mustard" with Induced Pluripotent Stem Cells: An Overview and Applications in Healthcare Paradigm. | Behl T et al. | β | 2022 | β |
| Defining the unknowns for cell therapies in Parkinson's disease. | Lane EL et al. | β | 2022 | β |
| Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinson's disease. | Pirooznia SK et al. | β | 2022 | β |
| Diseased, differentiated and difficult: Strategies for improved engineering of <i>in vitro</i> neurological systems. | Elder N et al. | β | 2022 | β |
| Disease Modeling of Neurodegenerative Disorders Using Direct Neural Reprogramming. | Legault EM et al. | β | 2022 | β |
| DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy. | Imberechts D et al. | β | 2022 | β |
| Does the Expression and Epigenetics of Genes Involved in Monogenic Forms of Parkinson's Disease Influence Sporadic Forms? | Lanore A et al. | β | 2022 | β |
| Electrophysiological Properties of Induced Pluripotent Stem Cell-Derived Midbrain Dopaminergic Neurons Correlate With Expression of Tyrosine Hydroxylase. | Rakovic A et al. | β | 2022 | β |
| Emerging Therapeutic Strategies for Parkinson's Disease and Future Prospects: A 2021 Update. | Gouda NA et al. | β | 2022 | β |
| Gene-independent therapeutic interventions to maintain and restore light sensitivity in degenerating photoreceptors. | Zuzic M et al. | β | 2022 | β |
| Generation and Cultivation of Transgene-Free Macaque and Baboon iPSCs Under Chemically Defined Conditions. | RodrΓguez-Polo I et al. | β | 2022 | β |
| Generation of a <i>NES</i>-mScarlet Red Fluorescent Reporter Human iPSC Line for Live Cell Imaging and Flow Cytometric Analysis and Sorting Using CRISPR-Cas9-Mediated Gene Editing. | Nouri P et al. | β | 2022 | β |
| Generation of human A9 dopaminergic pacemakers from induced pluripotent stem cells. | Li H et al. | β | 2022 | β |
| Generation of neuronal/glial mixed cultures from human induced pluripotent stem cells (hiPSCs). | Mangiameli E et al. | β | 2022 | β |
| Genomic, transcriptomic, and metabolomic profiles of hiPSC-derived dopamine neurons from clinically discordant brothers with identical PRKN deletions. | Cukier HN et al. | β | 2022 | β |
| Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease. | Brockhausen I et al. | β | 2022 | β |
| Gradient biomimetic platforms for neurogenesis studies. | Havins L et al. | β | 2022 | β |
| High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification. | Vuidel A et al. | β | 2022 | β |
| Human Brain-Based Models Provide a Powerful Tool for the Advancement of Parkinson's Disease Research and Therapeutic Development. | McComish SF et al. | β | 2022 | β |
| Human-Induced Pluripotent Stem Cell-Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases. | Kiris E | β | 2022 | β |
| Human iPSC-Derived Neural Models for Studying Alzheimer's Disease: from Neural Stem Cells to Cerebral Organoids. | Barak M et al. | β | 2022 | β |
| Human midbrain dopaminergic neuronal differentiation markers predict cell therapy outcomes in a Parkinson's disease model. | Xu P et al. | β | 2022 | β |
| Identification of DOT1L inhibitor in a screen for factors that promote dopaminergic neuron survival. | Cui J et al. | β | 2022 | β |
| <i>In Vivo</i> Generation of Organs by Blastocyst Complementation: Advances and Challenges. | Founta KM et al. | β | 2022 | β |
| Induced pluripotent stem cell-derived and directly reprogrammed neurons to study neurodegenerative diseases: The impact of aging signatures. | Aversano S et al. | β | 2022 | β |
| Intracerebroventricular transplantation of human iPSC-derived neural stem cells (hiPSC-NSCs) into neonatal mice. | Luciani M et al. | β | 2022 | β |
| Investigating cell therapies in animal models of Parkinson's and Huntington's disease: Current challenges and considerations. | Lelos MJ | β | 2022 | β |
| Kidney organoid derived from renal tissue stem cells is a useful tool for histopathological assessment of nephrotoxicity in a cisplatin-induced acute renal tubular injury model. | Ueno S et al. | β | 2022 | β |
| LGALS3 (galectin 3) mediates an unconventional secretion of SNCA/Ξ±-synuclein in response to lysosomal membrane damage by the autophagic-lysosomal pathway in human midbrain dopamine neurons. | Burbidge K et al. | β | 2022 | β |
| Long-Term Evaluation of Intranigral Transplantation of Human iPSC-Derived Dopamine Neurons in a Parkinson's Disease Mouse Model. | Brot S et al. | β | 2022 | β |
| LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease. | Kedariti M et al. | β | 2022 | β |
| Metabolic Profile Variations along the Differentiation of Human-Induced Pluripotent Stem Cells to Dopaminergic Neurons. | Carsana EV et al. | β | 2022 | β |
| MGE-Like Neural Progenitor Cell Survival and Expression of Parvalbumin and Proenkephalin in a Jaundiced Rat Model of Kernicterus. | Yang FC et al. | β | 2022 | β |
| Microfabricated disk technology: Rapid scale up in midbrain organoid generation. | Mohamed NV et al. | β | 2022 | β |
| Mitochondrial dysfunction of induced pluripotent stem cells-based neurodegenerative disease modeling and therapeutic strategy. | Luo HM et al. | β | 2022 | β |
| Modeling and Targeting Neuroglial Interactions with Human Pluripotent Stem Cell Models. | Bigarreau J et al. | β | 2022 | β |
| Modeling native and seeded Synuclein aggregation and related cellular dysfunctions in dopaminergic neurons derived by a new set of isogenic iPSC lines with SNCA multiplications. | Iannielli A et al. | β | 2022 | β |
| Modelling ciliopathy phenotypes in human tissues derived from pluripotent stem cells with genetically ablated cilia. | Cruz NM et al. | β | 2022 | β |
| Morphological Characterization of Astrocytes in a Xenograft of Human iPSCDerived Neural Precursor Cells. | Voronkov DN et al. | β | 2022 | β |
| Multifunctional role of natural products for the treatment of Parkinson's disease: At a glance. | Rahman MM et al. | β | 2022 | β |
| Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson's disease. | Panicker N et al. | β | 2022 | β |
| Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease. | Hiller BM et al. | β | 2022 | β |
| Oxidation and RGD Modification Affect the Early Neural Differentiation of Murine Embryonic Stem Cells Cultured in Core-Shell Alginate Hydrogel Microcapsules. | Dumbleton J et al. | β | 2022 | β |
| Parkin Deficiency Impairs Mitochondrial DNA Dynamics and Propagates Inflammation. | Wasner K et al. | β | 2022 | β |
| Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous Ξ±-synuclein in human neurons. | Fonseca-Ornelas L et al. | β | 2022 | β |
| Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling. | Grekhnev DA et al. | β | 2022 | β |
| PBX1 attenuates 6-OHDA-induced oxidative stress and apoptosis and affects PINK1/PARKIN expression in dopaminergic neurons via FOXA1. | Li B et al. | β | 2022 | β |
| Pluripotent stem cell strategies for rebuilding the human brain. | Limone F et al. | β | 2022 | β |
| Pretreatment with Perlecan-Conjugated Laminin-E8 Fragment Enhances Maturation of Grafted Dopaminergic Progenitors in Parkinson's Disease Model. | Adachi H et al. | β | 2022 | β |
| Protective role of mRNA demethylase FTO on axon guidance molecules of nigro-striatal projection system in manganese-induced parkinsonism. | Qi Z et al. | β | 2022 | β |
| Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson's disease in midbrain dopaminergic neurons. | Virdi GS et al. | β | 2022 | β |
| Rational design of injectable conducting polymer-based hydrogels for tissue engineering. | Yu C et al. | β | 2022 | β |
| Real-time fiber-optic recording of acute-ischemic-stroke signatures. | Pochechuev MS et al. | β | 2022 | β |
| Recent Neurotherapeutic Strategies to Promote Healthy Brain Aging: Are we there yet? | Kim CK et al. | β | 2022 | β |
| Recombinant pro-CTSD (cathepsin D) enhances SNCA/Ξ±-Synuclein degradation in Ξ±-Synucleinopathy models. | Prieto Huarcaya S et al. | β | 2022 | β |
| Reduced synaptic activity and dysregulated extracellular matrix pathways in midbrain neurons from Parkinson's disease patients. | Stern S et al. | β | 2022 | β |
| Rescue of Ξ±-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking. | Stojkovska I et al. | β | 2022 | β |
| Robust derivation of transplantable dopamine neurons from human pluripotent stem cells by timed retinoic acid delivery. | Alekseenko Z et al. | β | 2022 | β |
| Sensitive detection of electrophysiology and dopamine vesicular exocytosis of hESC-derived dopaminergic neurons using multifunctional microelectrode array. | He E et al. | β | 2022 | β |
| Sequestration of Inflammation in Parkinson's Disease via Stem Cell Therapy. | Gordon J et al. | β | 2022 | β |
| Simplifying cell fate map by determining lineage history of core pathway activation during fate specification. | Huang Z | β | 2022 | β |
| Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease. | Novak G et al. | β | 2022 | β |
| Single-cell transcriptomics reveals the cell fate transitions of human dopaminergic progenitors derived from hESCs. | Liang L et al. | β | 2022 | β |
| S-Nitrosylation of p62 Inhibits Autophagic Flux to Promote Ξ±-Synuclein Secretion and Spread in Parkinson's Disease and Lewy Body Dementia. | Oh CK et al. | β | 2022 | β |
| Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease. | Lane EL et al. | β | 2022 | β |
| Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells. | Kim J et al. | β | 2022 | β |
| Stem Cells as a Potential Therapeutic Option for Treating Neurodegenerative Diseases. | Aishwarya L et al. | β | 2022 | β |
| Stem Cell Transplantation for Parkinson's Disease: Current Challenges and Perspectives. | Zeng X et al. | β | 2022 | β |
| Structural Plasticity of Dopaminergic Neurons Requires the Activation of the D3R-nAChR Heteromer and the PI3K-ERK1/2/Akt-Induced Expression of c-Fos and p70S6K Signaling Pathway. | Mutti V et al. | β | 2022 | β |
| Synapsin III Regulates Dopaminergic Neuron Development in Vertebrates. | Faustini G et al. | β | 2022 | β |
| Synergic action of L-acetylcarnitine and L-methylfolate in Mouse Models of Stress-Related Disorders and Human iPSC-Derived Dopaminergic Neurons. | Orlando R et al. | β | 2022 | β |
| The Application of Brain Organoids in Assessing Neural Toxicity. | Fan P et al. | β | 2022 | β |
| The Immunomodulatory Potential Role of Mesenchymal Stem Cells in Diseases of the Central Nervous System. | Rufino RA et al. | β | 2022 | β |
| The long-term survival and functional maturation of human iNPC-derived neurons in the basal forebrain of cynomolgus monkeys. | Feng S et al. | β | 2022 | β |
| Therapeutic function of iPSCs-derived primitive neuroepithelial cells in a rat model of Parkinson's disease. | Guo Y et al. | β | 2022 | β |
| The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches. | Drobny A et al. | β | 2022 | β |
| Tissue-Engineered Models of the Human Brain: State-of-the-Art Analysis and Challenges. | Tarricone G et al. | β | 2022 | β |
| Transcriptomic characterization of tissues from patients and subsequent pathway analyses reveal biological pathways that are implicated in spastic ataxia. | Kakouri AC et al. | β | 2022 | β |
| Transcriptomics analysis of human iPSC-derived dopaminergic neurons reveals a novel model for sporadic Parkinson's disease. | Krauskopf J et al. | β | 2022 | β |
| Transdifferentiation of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Dopaminergic Neurons in a Three-Dimensional Culture. | Moayeri A et al. | β | 2022 | β |
| 16p11.2 deletion is associated with hyperactivation of human iPSC-derived dopaminergic neuron networks and is rescued by RHOA inhibition in vitro. | Sundberg M et al. | β | 2021 | β |
| Activation of HERV-K(HML-2) disrupts cortical patterning and neuronal differentiation by increasing NTRK3. | Padmanabhan Nair V et al. | β | 2021 | β |
| Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication. | Fukusumi H et al. | β | 2021 | β |
| Alzheimer's disease and its treatment by different approaches: A review. | Srivastava S et al. | β | 2021 | β |
| A mitochondrial membrane-bridging machinery mediates signal transduction of intramitochondrial oxidation. | Li L et al. | β | 2021 | β |
| A monolayer hiPSC culture system for autophagy/mitophagy studies in human dopaminergic neurons. | Stathakos P et al. | β | 2021 | β |
| Analysis of extracellular vesicles as a potential index for monitoring differentiation of neural lineage cells from induced pluripotent stem cells. | Saito H et al. | β | 2021 | β |
| Analysis of lysosomal hydrolase trafficking and activity in human iPSC-derived neuronal models. | Cuddy LK et al. | β | 2021 | β |
| Applying stem cells and CRISPR engineering to uncover the etiology of schizophrenia. | Michael Deans PJ et al. | β | 2021 | β |
| A preview of selected articles. | Atkinson SP | β | 2021 | β |
| Atypical Neurogenesis in Induced Pluripotent Stem Cells From Autistic Individuals. | Adhya D et al. | β | 2021 | β |
| Autologous Transplantation for Parkinson's Disease Patients: Feasibility and Challenge. | Zhang Q et al. | β | 2021 | β |
| Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys. | Tao Y et al. | β | 2021 | β |
| Auto-qPCR; a python-based web app for automated and reproducible analysis of qPCR data. | Maussion G et al. | β | 2021 | β |
| Biofunctionalised bacterial cellulose scaffold supports the patterning and expansion of human embryonic stem cell-derived dopaminergic progenitor cells. | Robbins M et al. | β | 2021 | β |
| Biphasic Activation of WNT Signaling Facilitates the Derivation of Midbrain Dopamine Neurons from hESCs for Translational Use. | Kim TW et al. | β | 2021 | β |
| Brain Repair by Cell Replacement via In Situ Neuronal Reprogramming. | Qian H et al. | β | 2021 | β |
| Bringing Advanced Therapies for Parkinson's Disease to the Clinic: The Scientist's Perspective. | Tomishima M et al. | β | 2021 | β |
| Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated Functionality and Modified Ξ±-Synuclein Degradation Properties. | Bunk J et al. | β | 2021 | β |
| Chemical and Biological Molecules Involved in Differentiation, Maturation, and Survival of Dopaminergic Neurons in Health and Parkinson's Disease: Physiological Aspects and Clinical Implications. | Gaggi G et al. | β | 2021 | β |
| Clinical Trial for Parkinson's Disease Gets a Green Light in the US. | Takahashi J | β | 2021 | β |
| Combination of Drugs and Cell Transplantation: More Beneficial Stem Cell-Based Regenerative Therapies Targeting Neurological Disorders. | Nishimura K et al. | β | 2021 | β |
| Comprehensive Perspectives on Experimental Models for Parkinson's Disease. | Ke M et al. | β | 2021 | β |
| Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders. | Benchoua A et al. | β | 2021 | β |
| Current Developments in Cell Replacement Therapy for Parkinson's Disease. | Guo X et al. | β | 2021 | β |
| Current State-of-the-Art and Unresolved Problems in Using Human Induced Pluripotent Stem Cell-Derived Dopamine Neurons for Parkinson's Disease Drug Development. | Antonov SA et al. | β | 2021 | β |
| Deconstructing and reconstructing the human brain with regionally specified brain organoids. | Xiang Y et al. | β | 2021 | β |
| Deep learning-based predictive identification of neural stem cell differentiation. | Zhu Y et al. | β | 2021 | β |
| Dementia with Lewy bodies-associated Γ-synuclein mutations V70M and P123H cause mutation-specific neuropathological lesions. | Psol M et al. | β | 2021 | β |
| Detection of pathological alpha-synuclein aggregates in human iPSC-derived neurons and tissue. | Stojkovska I et al. | β | 2021 | β |
| Differentiation of Human Pluripotent Stem Cells Into Specific Neural Lineages. | Chang CY et al. | β | 2021 | β |
| Direct Conversion of Human Fibroblasts to Induced Neurons. | Zhou-Yang L et al. | β | 2021 | β |
| Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models. | Burbulla LF et al. | β | 2021 | β |
| Dopamine Neuron Diversity: Recent Advances and Current Challenges in Human Stem Cell Models and Single Cell Sequencing. | Fiorenzano A et al. | β | 2021 | β |
| Dopamine promotes the neurodegenerative potential of Ξ²-synuclein. | Raina A et al. | β | 2021 | β |
| Dynamic landscape of chromatin accessibility and transcriptomic changes during differentiation of human embryonic stem cells into dopaminergic neurons. | MelΓ©ndez-RamΓrez C et al. | β | 2021 | β |
| Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease. | Kim S et al. | β | 2021 | β |
| Effects of Surface Chemistry Interaction on Primary Neural Stem Cell Neurosphere Responses. | Joseph G et al. | β | 2021 | β |
| Efficient generation of dopaminergic induced neuronal cells with midbrain characteristics. | Ng YH et al. | β | 2021 | β |
| Electrochemical Impedance Spectroscopy as a Tool for Monitoring Cell Differentiation from Floor Plate Progenitors to Midbrain Neurons in Real Time. | Elghajiji A et al. | β | 2021 | β |
| Electrophysiological Quality Control of Human Dopaminergic Neurons: Are We Doing Enough? | Seutin V | β | 2021 | β |
| Embryonic stem cell-derived extracellular vesicles promote the recovery of kidney injury. | Yu L et al. | β | 2021 | β |
| Embryonic stem cells go from bench to bedside for Parkinson's disease. | Parish CL et al. | β | 2021 | β |
| Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases. | Trudler D et al. | β | 2021 | β |
| Emerging Opportunities in Human Pluripotent Stem-Cells Based Assays to Explore the Diversity of Botulinum Neurotoxins as Future Therapeutics. | Duchesne de Lamotte J et al. | β | 2021 | β |
| Enhanced differentiation of human induced pluripotent stem cells toward the midbrain dopaminergic neuron lineage through GLYPICAN-4 downregulation. | Corti S et al. | β | 2021 | β |
| Enzymatically Forming Intranuclear Peptide Assemblies for Selectively Killing Human Induced Pluripotent Stem Cells. | Liu S et al. | β | 2021 | β |
| Epigenetic regulation during human cortical development: Seq-ing answers from the brain to the organoid. | Lewis EMA et al. | β | 2021 | β |
| FGF, Mechanism of Action, Role in Parkinson's Disease, and Therapeutics. | Liu Y et al. | β | 2021 | β |
| Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function. | Barbuti PA et al. | β | 2021 | β |
| Generation and Breeding of <i>EGFP</i>-Transgenic Marmoset Monkeys: Cell Chimerism and Implications for Disease Modeling. | Drummer C et al. | β | 2021 | β |
| Generation of caudal-type serotonin neurons and hindbrain-fate organoids from hPSCs. | Valiulahi P et al. | β | 2021 | β |
| Generation of hiPSC-Derived Functional Dopaminergic Neurons in Alginate-Based 3D Culture. | Gilmozzi V et al. | β | 2021 | β |
| Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies. | McTague A et al. | β | 2021 | β |
| Grafts Derived from an Ξ±-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease. | Shrigley S et al. | β | 2021 | β |
| High-throughput generation of midbrain dopaminergic neuron organoids from reporter human pluripotent stem cells. | Sarrafha L et al. | β | 2021 | β |
| hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible. | Rivetti di Val Cervo P et al. | β | 2021 | β |
| Human Amniotic Epithelial Cells Alleviate a Mouse Model of Parkinson's Disease Mainly by Neuroprotective, Anti-Oxidative and Anti-Inflammatory Factors. | Zhang J et al. | β | 2021 | β |
| Human inducible pluripotent stem cells: Realization of initial promise in drug discovery. | Kleiman RJ et al. | β | 2021 | β |
| Human neural organoids: Models for developmental neurobiology and disease. | Guy B et al. | β | 2021 | β |
| Human stem cell models to study host-virus interactions in the central nervous system. | Harschnitz O et al. | β | 2021 | β |
| Human stem cells harboring a suicide gene improve theΒ safety and standardisation of neural transplants in Parkinsonian rats. | de Luzy IR et al. | β | 2021 | β |
| Identification of ASCL1 as a determinant for human iPSC-derived dopaminergic neurons. | Earley AM et al. | β | 2021 | β |
| Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation. | Bono F et al. | β | 2021 | β |
| Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Familial Parkinson's Disease Patients Display Ξ±-Synuclein Pathology and Abnormal Mitochondrial Morphology. | Diao X et al. | β | 2021 | β |
| Inhibition of Ξ²-catenin dependent WNT signalling upregulates the transcriptional repressor NR0B1 and downregulates markers of an A9 phenotype in human embryonic stem cell-derived dopaminergic neurons: Implications for Parkinson's disease. | Haynes JM et al. | β | 2021 | β |
| In Parkinson's patient-derived dopamine neurons, the triplication of Ξ±-synuclein locus induces distinctive firing pattern by impeding D2 receptor autoinhibition. | Lin M et al. | β | 2021 | β |
| In vivo conversion of dopamine neurons in mouse models of Parkinson's disease - a future approach for regenerative therapy? | Parmar M et al. | β | 2021 | β |
| Making Sense of Patient-Derived iPSCs, Transdifferentiated Neurons, Olfactory Neuronal Cells, and Cerebral Organoids as Models for Psychiatric Disorders. | Unterholzner J et al. | β | 2021 | β |
| Metaxins are core components of mitochondrial transport adaptor complexes. | Zhao Y et al. | β | 2021 | β |
| Midbrain organoids with an <i>SNCA</i> gene triplication model key features of synucleinopathy. | Mohamed NV et al. | β | 2021 | β |
| Mitochondrial dysfunction in neurodegenerative diseases: A focus on iPSC-derived neuronal models. | Trombetta-Lima M et al. | β | 2021 | β |
| Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function inβvivo. | Hiller BM et al. | β | 2021 | β |
| Mouse Embryonic Stem Cells Expressing GDNF Show Enhanced Dopaminergic Differentiation and Promote Behavioral Recovery After Grafting in Parkinsonian Rats. | Lara-Rodarte R et al. | β | 2021 | β |
| Multifactoriality of Parkinson's Disease as Explored Through Human Neural Stem Cells and Their Transplantation in Middle-Aged Parkinsonian Mice. | Nelke A et al. | β | 2021 | β |
| Multifunctional nanoscale lanthanide metal-organic framework based ratiometric fluorescence paper microchip for visual dopamine assay. | Yu L et al. | β | 2021 | β |
| Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALS. | Lee H et al. | β | 2021 | β |
| Neural In Vitro Models for Studying Substances Acting on the Central Nervous System. | Fritsche E et al. | β | 2021 | β |
| Neural precursors cells expanded in a 3D micro-engineered niche present enhanced therapeutic efficacy <i>in vivo</i>. | Carelli S et al. | β | 2021 | β |
| Neural stem cells derived from human midbrain organoids as a stable source for treating Parkinson's disease: Midbrain organoid-NSCs (Og-NSC) as a stable source for PD treatment. | Kim SW et al. | β | 2021 | β |
| Neural stem cell therapy for brain disease. | Zhao L et al. | β | 2021 | β |
| Neural tube patterning: from a minimal model for rostrocaudal patterning toward an integrated 3D model. | Brambach M et al. | β | 2021 | β |
| Neuronal cell-based medicines from pluripotent stem cells: Development, production, and preclinical assessment. | Sun Y et al. | β | 2021 | β |
| Neuronal replacement: Concepts, achievements, and call for caution. | GΓΆtz M et al. | β | 2021 | β |
| Novel culture system via wirelessly controllable optical stimulation of the FGF signaling pathway for human and pig pluripotency. | Choi IY et al. | β | 2021 | β |
| On the Road from Phenotypic Plasticity to Stem Cell Therapy. | Iacovitti L | β | 2021 | β |
| Optimization of the nutritional environment for differentiation of human-induced pluripotent stem cells using design of experiments-A proof of concept. | Esteban PP et al. | β | 2021 | β |
| Parkinson's disease patient-specific neuronal networks carrying the LRRK2 G2019S mutation unveil early functional alterations that predate neurodegeneration. | Carola G et al. | β | 2021 | β |
| Patterning inconsistencies restrict the true potential of dopaminergic neurons derived from human induced pluripotent stem cells. | Mahajani S et al. | β | 2021 | β |
| Pharmacological Modulation of Neurite Outgrowth in Human Neural Progenitor Cells by Inhibiting Non-muscle Myosin II. | Lilienberg J et al. | β | 2021 | β |
| Pluripotent stem cell derived dopaminergic subpopulations model the selective neuron degeneration in Parkinson's disease. | Oosterveen T et al. | β | 2021 | β |
| Pluripotent Stem Cell Derived Neurons as In Vitro Models for Studying Autosomal Recessive Parkinson's Disease (ARPD): PLA2G6 and Other Gene Loci. | Gopurappilly R | β | 2021 | β |
| Population-scale single-cell RNA-seq profiling across dopaminergic neuron differentiation. | Jerber J et al. | β | 2021 | β |
| Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. | Piao J et al. | β | 2021 | β |
| Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications. | Hu XM et al. | β | 2021 | β |
| Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. | Barbuti PA et al. | β | 2021 | β |
| Regenerative medicine for neurological diseases-will regenerative neurosurgery deliver? | Burns TC et al. | β | 2021 | β |
| Reinforced-hydrogel encapsulated hMSCs towards brain injury treatment by trans-septal approach. | Sultan MT et al. | β | 2021 | β |
| Restoring lost nigrostriatal fibers in Parkinson's disease based on clinically-inspired design criteria. | GordiΓ‘n-VΓ©lez WJ et al. | β | 2021 | β |
| Role of SHH in Patterning Human Pluripotent Cells towards Ventral Forebrain Fates. | Brady MV et al. | β | 2021 | β |
| Serotonin-specific neurons differentiated from human iPSCs form distinct subtypes with synaptic protein assembly. | Jansch C et al. | β | 2021 | β |
| Single-Cell Profiling of Coding and Noncoding Genes in Human Dopamine Neuron Differentiation. | Nilsson F et al. | β | 2021 | β |
| Single-Cell RNA Sequencing in Parkinson's Disease. | Ma SX et al. | β | 2021 | β |
| Spatial RNA Sequencing Identifies Robust Markers of Vulnerable and Resistant Human Midbrain Dopamine Neurons and Their Expression in Parkinson's Disease. | Aguila J et al. | β | 2021 | β |
| Synthetic mRNA-based differentiation method enables early detection of Parkinson's phenotypes in neurons derived from Gaucher disease-induced pluripotent stem cells. | Akiyama T et al. | β | 2021 | β |
| Targeted attenuation of elevated histone marks at SNCA alleviates Ξ±-synuclein in Parkinson's disease. | Guhathakurta S et al. | β | 2021 | β |
| Targeting Ξ±-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models. | Spathopoulou A et al. | β | 2021 | β |
| The Different Molecular Code in Generation of Dopaminergic Neurons from Astrocytes and Mesenchymal Stem Cells. | Wang N et al. | β | 2021 | β |
| The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson's disease. | Qarin S et al. | β | 2021 | β |
| The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease. | de Rus Jacquet A et al. | β | 2021 | β |
| The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders. | Ginsberg SD et al. | β | 2021 | β |
| The potential therapy with dental tissue-derived mesenchymal stem cells in Parkinson's disease. | Xiao Z et al. | β | 2021 | β |
| The quest of cell surface markers for stem cell therapy. | Meyfour A et al. | β | 2021 | β |
| TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson's disease. | Seo BA et al. | β | 2021 | β |
| Trophoblast glycoprotein is a marker for efficient sorting of ventral mesencephalic dopaminergic precursors derived from human pluripotent stem cells. | Yoo JE et al. | β | 2021 | β |
| Ultrahigh Efficiency and Minimalist Intracellular Delivery of Macromolecules Mediated by Latent-Photothermal Surfaces. | Tang H et al. | β | 2021 | β |
| Ξ±-synuclein pathogenesis in hiPSC models of Parkinson's disease. | Baena-Montes JM et al. | β | 2021 | β |
| A critical look: Challenges in differentiating human pluripotent stem cells into desired cell types and organoids. | Fowler JL et al. | β | 2020 | β |
| Advanced Materials to Enhance Central Nervous System Tissue Modeling and Cell Therapy. | Muckom RJ et al. | β | 2020 | β |
| Advancement in the modelling and therapeutics of Parkinson's disease. | Rai SN et al. | β | 2020 | β |
| Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. | Liu G et al. | β | 2020 | β |
| Advantages and Recent Developments of Autologous Cell Therapy for Parkinson's Disease Patients. | Osborn TM et al. | β | 2020 | β |
| Assessing Human Embryonic Stem Cell-Derived Dopaminergic Neuron Progenitor Transplants Using Non-invasive Imaging Techniques. | Mousavinejad M et al. | β | 2020 | β |
| Balancing Expectations for Success in Stem Cell-Based Clinical Trials for Parkinson's Disease. | Lindvall O | β | 2020 | β |
| Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model. | Zenchak JR et al. | β | 2020 | β |
| Cell therapy for Parkinson's disease is coming of age: current challenges and future prospects with a focus on immunomodulation. | Wenker SD et al. | β | 2020 | β |
| CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease. | Bengoa-Vergniory N et al. | β | 2020 | β |
| Columnar Injection for Intracerebral Cell Therapy. | Schweitzer JS et al. | β | 2020 | β |
| Cryopreservation of Human Midbrain Dopaminergic Neural Progenitor Cells Poised for Neuronal Differentiation. | Drummond NJ et al. | β | 2020 | β |
| Current Status of Stem Cell-Derived Therapies for Parkinson's Disease: From Cell Assessment and Imaging Modalities to Clinical Trials. | Jang SE et al. | β | 2020 | β |
| Current understanding of lymphatic vessels in the central nervous system. | Tamura R et al. | β | 2020 | β |
| Deconstructing Neurogenesis, Transplantation and Genome-Editing as Neural Repair Strategies in Brain Disease. | Chohan MO | β | 2020 | β |
| Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. | Kumar M et al. | β | 2020 | β |
| Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. | Kim JW et al. | β | 2020 | β |
| Developmental deficits and early signs of neurodegeneration revealed by PD patient derived dopamine neurons. | Luo F et al. | β | 2020 | β |
| Development and Application of High-Throughput Single Cell Lipid Profiling: A Study of <i>SNCA-A53T</i> Human Dopamine Neurons. | Snowden SG et al. | β | 2020 | β |
| Development and Differentiation of Midbrain Dopaminergic Neuron: From Bench to Bedside. | Wang M et al. | β | 2020 | β |
| Direct conversion of human fibroblasts into dopaminergic neuron-like cells using small molecules and protein factors. | Qin H et al. | β | 2020 | β |
| Dopaminergic Progenitors Derived From Epiblast Stem Cells Function Similarly to Primary VM-Derived Progenitors When Transplanted Into a Parkinson's Disease Model. | Precious SV et al. | β | 2020 | β |
| Dopamine Sensing Based on Ultrathin Fluorescent Metal-Organic Nanosheets. | Moghzi F et al. | β | 2020 | β |
| Emerging regenerative medicine and tissue engineering strategies for Parkinson's disease. | Harris JP et al. | β | 2020 | β |
| Energy Metabolism Disturbances in Cell Models of PARK2 CNV Carriers with ADHD. | Palladino VS et al. | β | 2020 | β |
| Engraftable Induced Pluripotent Stem Cell-Derived Neural Precursors for Brain Repair. | Zygogianni O et al. | β | 2020 | β |
| From Skin to Brain: A Parkinson's Disease Patient Transplanted with His Own Cells. | Parmar M et al. | β | 2020 | β |
| Gelator length precisely tunes supramolecular hydrogel stiffness and neuronal phenotype in 3D culture. | Godbe JM et al. | β | 2020 | β |
| Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We? | Buttery PC et al. | β | 2020 | β |
| Generation of Pluripotent Stem Cells Using Somatic Cell Nuclear Transfer and Induced Pluripotent Somatic Cells from African Green Monkeys. | Chung YG et al. | β | 2020 | β |
| Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells. | Tran J et al. | β | 2020 | β |
| Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice. | Zhou H et al. | β | 2020 | β |
| hiPSC-Derived Neurons Provide a Robust and Physiologically Relevant <i>In Vitro</i> Platform to Test Botulinum Neurotoxins. | Lamotte JD et al. | β | 2020 | β |
| Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. | Song B et al. | β | 2020 | β |
| Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy. | Seranova E et al. | β | 2020 | β |
| Human iPSCs derived astrocytes rescue rotenone-induced mitochondrial dysfunction and dopaminergic neurodegeneration in vitro by donating functional mitochondria. | Cheng XY et al. | β | 2020 | β |
| Human Mesenchymal Stromal Cells Unveil an Unexpected Differentiation Potential toward the Dopaminergic Neuronal Lineage. | Gaggi G et al. | β | 2020 | β |
| Human Pluripotent Stem Cells: Applications and Challenges for Regenerative Medicine and Disease Modeling. | Miranda CC et al. | β | 2020 | β |
| Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges. | Ford E et al. | β | 2020 | β |
| Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations. | Kolagar TA et al. | β | 2020 | β |
| Impact of Ξ±-synuclein pathology on transplanted hESC-derived dopaminergic neurons in a humanized Ξ±-synuclein rat model of PD. | Hoban DB et al. | β | 2020 | β |
| Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening. | Chang CY et al. | β | 2020 | β |
| Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems. | Rehbach K et al. | β | 2020 | β |
| Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells. | Powell SK et al. | β | 2020 | β |
| In vitro modeling for inherited neurological diseases using induced pluripotent stem cells: from 2D to organoid. | Nam KH et al. | β | 2020 | β |
| iPS cell-based therapy for Parkinson's disease: A Kyoto trial. | Takahashi J | β | 2020 | β |
| iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates. | Laperle AH et al. | β | 2020 | β |
| Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases? | Salado-Manzano C et al. | β | 2020 | β |
| Mesenchymal stem cells modulate misfolded Ξ±-synuclein in parkinsonian disorders: A multitarget disease-modifying strategy. | Shin JY et al. | β | 2020 | β |
| Midbrain Dopaminergic Neuron Development at the Single Cell Level: <i>In vivo</i> and in Stem Cells. | ΓsgrΓmsdΓ³ttir ES et al. | β | 2020 | β |
| Midbrain Organoids: A New Tool to Investigate Parkinson's Disease. | Smits LM et al. | β | 2020 | β |
| Missing heritability in Parkinson's disease: the emerging role of non-coding genetic variation. | Ohnmacht J et al. | β | 2020 | β |
| Modeling genetic epilepsies in a dish. | Niu W et al. | β | 2020 | β |
| Modeling Poliovirus Infection Using Human Engineered Neural Tissue Enriched With Motor Neuron Derived From Embryonic Stem Cells. | Cosset Γ et al. | β | 2020 | β |
| Molecular Regulation in Dopaminergic Neuron Development. Cues to Unveil Molecular Pathogenesis and Pharmacological Targets of Neurodegeneration. | Volpicelli F et al. | β | 2020 | β |
| Natural Killer Cell Alloreactivity Against Human Induced Pluripotent Stem Cells and Their Neuronal Derivatives into Dopaminergic Neurons. | de Rham C et al. | β | 2020 | β |
| Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques. | Collo G et al. | β | 2020 | β |
| Neuronal Replacement as a Tool for Basal Ganglia Circuitry Repair: 40 Years in Perspective. | BjΓΆrklund A et al. | β | 2020 | β |
| Neuronal Trans-differentiation by Transcription Factors Ascl1 and Nurr1: Induction of a Dopaminergic Neurotransmitter Phenotype in Cortical GABAergic Neurons. | Raina A et al. | β | 2020 | β |
| Non-Human Primate iPSC Generation, Cultivation, and Cardiac Differentiation under Chemically Defined Conditions. | Stauske M et al. | β | 2020 | β |
| Non-immunogenic Induced Pluripotent Stem Cells, a Promising Way Forward for Allogenic Transplantations for Neurological Disorders. | Frederiksen HR et al. | β | 2020 | β |
| Novel genetic features of human and mouse Purkinje cell differentiation defined by comparative transcriptomics. | Buchholz DE et al. | β | 2020 | β |
| On the Right Track to Treat Movement Disorders: Promising Therapeutic Approaches for Parkinson's and Huntington's Disease. | Troncoso-Escudero P et al. | β | 2020 | β |
| Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery. | Marotta N et al. | β | 2020 | β |
| Origin of the Induced Pluripotent Stem Cells Affects Their Differentiation into Dopaminergic Neurons. | Chlebanowska P et al. | β | 2020 | β |
| Parkinson's disease, aging and adult neurogenesis: Wnt/Ξ²-catenin signalling as the key to unlock the mystery of endogenous brain repair. | Marchetti B et al. | β | 2020 | β |
| Parkinson's disease: From bench to bedside. | Draoui A et al. | β | 2020 | β |
| Pathogenic Pathways in Early-Onset Autosomal Recessive Parkinson's Disease Discovered Using Isogenic Human Dopaminergic Neurons. | Ahfeldt T et al. | β | 2020 | β |
| Patient-Derived Midbrain Organoids to Explore the Molecular Basis of Parkinson's Disease. | Galet B et al. | β | 2020 | β |
| Peptide-Based Scaffolds for the Culture and Transplantation of Human Dopaminergic Neurons. | Francis NL et al. | β | 2020 | β |
| Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. | Schweitzer JS et al. | β | 2020 | β |
| Pluripotent Stem Cell Therapies for Parkinson Disease: Present Challenges and Future Opportunities. | Kim TW et al. | β | 2020 | β |
| Preclinical evaluation of patient-derived cells shows promise for Parkinson's disease. | Takahashi J | β | 2020 | β |
| Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. | Doi D et al. | β | 2020 | β |
| PVDF Nanofiber Scaffold Coated with a Vitronectin Peptide Facilitates the Neural Differentiation of Human Embryonic Stem Cells. | Jeon BM et al. | β | 2020 | β |
| Replacing what's lost: a new era of stem cell therapy for Parkinson's disease. | Fan Y et al. | β | 2020 | β |
| Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease. | Henchcliffe C et al. | β | 2020 | β |
| Role of Chromatin Remodeling Genes and TETs in the Development of Human Midbrain Dopaminergic Neurons. | Xiang L et al. | β | 2020 | β |
| Single cell transcriptomics identifies stem cell-derived graft composition in a model of Parkinson's disease. | TiklovΓ‘ K et al. | β | 2020 | β |
| Single-Cell Transcriptomics of Parkinson's Disease Human InΒ Vitro Models Reveals Dopamine Neuron-Specific Stress Responses. | Fernandes HJR et al. | β | 2020 | β |
| Small Molecules that Promote Self-Renewal of Stem Cells and Somatic Cell Reprogramming. | Chen G et al. | β | 2020 | β |
| SOX1 Is Required for the Specification of Rostral Hindbrain Neural Progenitor Cells from Human Embryonic Stem Cells. | Liu X et al. | β | 2020 | β |
| Stem Cell-Based Therapeutic Approaches to Restore Sensorineural Hearing Loss in Mammals. | Waqas M et al. | β | 2020 | β |
| Stem Cell-Based Therapies for Parkinson Disease. | Liu Z et al. | β | 2020 | β |
| Stem cell-directed therapies for osteoarthritis: The promise and the practice. | Ng J et al. | β | 2020 | β |
| Stem Cell Therapy for Parkinson's Disease. | Han F et al. | β | 2020 | β |
| Stimulation of L-type calcium channels increases tyrosine hydroxylase and dopamine in ventral midbrain cells induced from somatic cells. | Jefri M et al. | β | 2020 | β |
| The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinson's Disease. | Minakaki G et al. | β | 2020 | β |
| The fusiform gyrus exhibits an epigenetic signature for Alzheimer's disease. | Ma D et al. | β | 2020 | β |
| The future of stem cell therapies for Parkinson disease. | Parmar M et al. | β | 2020 | β |
| Toward Generating Subtype-Specific Mesencephalic Dopaminergic Neurons <i>in vitro</i>. | Cardoso T et al. | β | 2020 | β |
| Transcription Factor-Based Fate Specification and Forward Programming for Neural Regeneration. | Flitsch LJ et al. | β | 2020 | β |
| Ultrasensitive and rapid quantification of rare tumorigenic stem cells in hPSC-derived cardiomyocyte populations. | Wang Z et al. | β | 2020 | β |
| Use of 3D Organoids as a Model to Study Idiopathic Form of Parkinson's Disease. | Chlebanowska P et al. | β | 2020 | β |
| Viral Delivery of GDNF Promotes Functional Integration of Human Stem Cell Grafts in Parkinson's Disease. | Gantner CW et al. | β | 2020 | β |
| What we can learn from iPSC-derived cellular models of Parkinson's disease. | Caiazza MC et al. | β | 2020 | β |
| A compendious summary of Parkinson's disease patient-derived iPSCs in the first decade. | Ren C et al. | β | 2019 | β |
| Advances in stem cell research and therapeutic development. | De Luca M et al. | β | 2019 | β |
| A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease. | Burbulla LF et al. | β | 2019 | β |
| An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2. | Connor-Robson N et al. | β | 2019 | β |
| An Optimized Method for the Proteomic Analysis of Low Volumes of Cell Culture Media and the Secretome: The Application and the Demonstration of Altered Protein Expression in iPSC-Derived Neuronal Cell Lines from Parkinson's Disease Patients. | Baud A et al. | β | 2019 | β |
| A novel machine learning based approach for iPS progenitor cell identification. | Zhang H et al. | β | 2019 | β |
| Application of CRISPR/Cas9 editing and digital droplet PCR in human iPSCs to generate novel knock-in reporter lines to visualize dopaminergic neurons. | Γberbacher C et al. | β | 2019 | β |
| Are PARKIN patients ideal candidates for dopaminergic cell replacement therapies? | Kunath T et al. | β | 2019 | β |
| Automated minute scale RNA-seq of pluripotent stem cell differentiation reveals early divergence of human and mouse gene expression kinetics. | Barry C et al. | β | 2019 | β |
| Awareness and current knowledge of Parkinson's disease: a neurodegenerative disorder. | Khan AU et al. | β | 2019 | β |
| Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus. | Czaniecki C et al. | β | 2019 | β |
| Brain Organoids-A Bottom-Up Approach for Studying Human Neurodevelopment. | Karzbrun E et al. | β | 2019 | β |
| Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology. | Rodrigues RS et al. | β | 2019 | β |
| Cell-based therapy for Parkinson's disease: A journey through decades toward the light side of the Force. | Parmar M et al. | β | 2019 | β |
| Cellular alterations identified in pluripotent stem cell-derived midbrain spheroids generated from a female patient with progressive external ophthalmoplegia and parkinsonism who carries a novel variation (p.Q811R) in the POLG1 gene. | Chumarina M et al. | β | 2019 | β |
| Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. | Jamebozorgi K et al. | β | 2019 | β |
| Cellular Ξ±-synuclein pathology is associated with bioenergetic dysfunction in Parkinson's iPSC-derived dopamine neurons. | Zambon F et al. | β | 2019 | β |
| Chemical Conversion of Human Fetal Astrocytes into Neurons through Modulation of Multiple Signaling Pathways. | Yin JC et al. | β | 2019 | β |
| Comprehensive Cell Surface Antigen Analysis Identifies Transferrin Receptor Protein-1 (CD71) as a Negative Selection Marker for Human Neuronal Cells. | Menon V et al. | β | 2019 | β |
| Concise Review: Human-Animal Neurological Chimeras: Humanized Animals or Human Cells in an Animal? | Crane AT et al. | β | 2019 | β |
| Conversion of Quinazoline Modulators from Inhibitors to Activators of Ξ²-Glucocerebrosidase. | Zheng J et al. | β | 2019 | β |
| CRH Promotes the Neurogenic Activity of Neural Stem Cells in the Adult Hippocampus. | Koutmani Y et al. | β | 2019 | β |
| CRISPR/Cas9-mediated generation of a tyrosine hydroxylase reporter iPSC line for live imaging and isolation of dopaminergic neurons. | Calatayud C et al. | β | 2019 | β |
| Crosstalk of Intercellular Signaling Pathways in the Generation of Midbrain Dopaminergic Neurons In Vivo and from Stem Cells. | Brodski C et al. | β | 2019 | β |
| Cylinder Test to Assess Sensory-motor Function in a Mouse Model of Parkinson's Disease. | Magno LAV et al. | β | 2019 | β |
| Derivation of primitive neural stem cells from human-induced pluripotent stem cells. | Shin WJ et al. | β | 2019 | β |
| Differentiation of adult human retinal pigment epithelial cells into dopaminergic-like cells in vitro and in the recipient monkey brain. | Li S et al. | β | 2019 | β |
| Differentiation of human olfactory system-derived stem cells into dopaminergic neuron-like cells: A comparison between olfactory bulb and mucosa as two sources of stem cells. | Alizadeh R et al. | β | 2019 | β |
| Differentiation of Neural Stem Cells Derived from Induced Pluripotent Stem Cells into Dopaminergic Neurons. | Daadi MM | β | 2019 | β |
| Direct reprogramming into interneurons: potential for brain repair. | Pereira M et al. | β | 2019 | β |
| Doxycycline Masks the Genuine Effect of the Doxycycline-Inducible Transgene by Promoting Dopaminergic Neuron Differentiation from Human Pluripotent Stem Cells. | Cao D et al. | β | 2019 | β |
| Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. | Pitcairn C et al. | β | 2019 | β |
| Efficient Neural Differentiation of hPSCs by Extrinsic Signals Derived from Co-cultured Neural Stem or Precursor Cells. | Rhee YH et al. | β | 2019 | β |
| Emerging therapies in Parkinson disease - repurposed drugs and new approaches. | Elkouzi A et al. | β | 2019 | β |
| Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene. | Chen Y et al. | β | 2019 | β |
| Epigenetic Analysis in Human Neurons: Considerations for Disease Modeling in PD. | de Boni L et al. | β | 2019 | β |
| Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. | Siddiqi FH et al. | β | 2019 | β |
| From Schizophrenia Genetics to Disease Biology: Harnessing New Concepts and Technologies. | Duan J et al. | β | 2019 | β |
| Functional Cortical Axon Tracts Generated from Human Stem Cell-Derived Neurons. | Chen HI et al. | β | 2019 | β |
| Generation of a PARK2 homozygous knockout induced pluripotent stem cell line (GIBHi002-A-1) with two common isoforms abolished. | Zhang M et al. | β | 2019 | β |
| Harnessing stem cells and biomaterials to promote neural repair. | Bruggeman KF et al. | β | 2019 | β |
| hESC-Derived Dopaminergic Transplants Integrate into Basal Ganglia Circuitry in a Preclinical Model of Parkinson's Disease. | Adler AF et al. | β | 2019 | β |
| Homogenous generation of dopaminergic neurons from multiple hiPSC lines by transient expression of transcription factors. | Mahajani S et al. | β | 2019 | β |
| Human Brain Slice Culture: A Useful Tool to Study Brain Disorders and Potential Therapeutic Compounds. | Qi XR et al. | β | 2019 | β |
| Human-induced pluripotent stems cells as a model to dissect the selective neurotoxicity of methylmercury. | Prince LM et al. | β | 2019 | β |
| Human NPCs can degrade Ξ±-syn fibrils and transfer them preferentially in a cell contact-dependent manner possibly through TNT-like structures. | Grudina C et al. | β | 2019 | β |
| Human Pluripotent Stem Cells as Tools for Predicting Developmental Neural Toxicity of Chemicals: Strategies, Applications, and Challenges. | Liang S et al. | β | 2019 | β |
| Huntington's disease associated resistance to Mn neurotoxicity is neurodevelopmental stage and neuronal lineage dependent. | Joshi P et al. | β | 2019 | β |
| Hydroxyurea Facilitates Manifestation of Disease Relevant Phenotypes in Patients-Derived IPSCs-Based Modeling of Late-Onset Parkinson's Disease. | Tan Y et al. | β | 2019 | β |
| <i>In Vitro</i> Induction of Human Embryonic Stem Cells into the Midbrain Dopaminergic Neurons and Transplantation in Cynomolgus Monkey. | Qiu X et al. | β | 2019 | β |
| Immature mDA neurons ameliorate motor deficits in a 6-OHDA Parkinson's disease mouse model and are functional after cryopreservation. | Leitner D et al. | β | 2019 | β |
| Increased Lysosomal Exocytosis Induced by Lysosomal Ca<sup>2+</sup> Channel Agonists Protects Human Dopaminergic Neurons from Ξ±-Synuclein Toxicity. | Tsunemi T et al. | β | 2019 | β |
| Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease. | Weykopf B et al. | β | 2019 | β |
| Induced pluripotent stem cells in multiple system atrophy: recent developments and scientific challenges. | Ndayisaba A et al. | β | 2019 | β |
| Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing. | Artyukhova MA et al. | β | 2019 | β |
| Interspecies Organogenesis for Human Transplantation. | Crane AT et al. | β | 2019 | β |
| Intranasal Administration of Extracellular Vesicles Derived from Human Teeth Stem Cells Improves Motor Symptoms and Normalizes Tyrosine Hydroxylase Expression in the Substantia Nigra and Striatum of the 6-Hydroxydopamine-Treated Rats. | Narbute K et al. | β | 2019 | β |
| In Vivo Phenotyping of Familial Parkinson's Disease with Human Induced Pluripotent Stem Cells: A Proof-of-Concept Study. | Zygogianni O et al. | β | 2019 | β |
| Isolation of LMX1a Ventral Midbrain Progenitors Improves the Safety and Predictability of Human Pluripotent Stem Cell-Derived Neural Transplants in Parkinsonian Disease. | de Luzy IR et al. | β | 2019 | β |
| Ketamine increases the expression of GluR1 and GluR2 Ξ±-amino-3-hydroxy-5-methy-4-isoxazole propionate receptor subunits in human dopaminergic neurons differentiated from induced pluripotent stem cells. | Collo G et al. | β | 2019 | β |
| LIN28A loss of function is associated with Parkinson's disease pathogenesis. | Chang MY et al. | β | 2019 | β |
| Lipid Deprivation Induces a Stable, Naive-to-Primed Intermediate State of Pluripotency in Human PSCs. | Cornacchia D et al. | β | 2019 | β |
| Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons. | Riessland M et al. | β | 2019 | β |
| LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients. | Ysselstein D et al. | β | 2019 | β |
| Making NSC and Neurons from Patient-Derived Tissue Samples. | Mukherjee O et al. | β | 2019 | β |
| Midbrain Dopaminergic Neurons Differentiated from Human-Induced Pluripotent Stem Cells. | Tofoli FA et al. | β | 2019 | β |
| Minimally Invasive and Regenerative Therapeutics. | Ashammakhi N et al. | β | 2019 | β |
| Miro1 Marks Parkinson's Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinson's Models. | Hsieh CH et al. | β | 2019 | β |
| Misfolded Protein Linked Strategies Toward Biomarker Development for Neurodegenerative Diseases. | Kumar S et al. | β | 2019 | β |
| Modeling Cell-Cell Interactions in Parkinson's Disease Using Human Stem Cell-Based Models. | Simmnacher K et al. | β | 2019 | β |
| Modeling neuronopathic storage diseases with patient-derived culture systems. | Zunke F et al. | β | 2019 | β |
| Modeling Parkinson's disease in midbrain-like organoids. | Smits LM et al. | β | 2019 | β |
| Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells. | Naphade S et al. | β | 2019 | β |
| Neural Lineage Differentiation From Pluripotent Stem Cells to Mimic Human Brain Tissues. | Hong YJ et al. | β | 2019 | β |
| Neuronal migration in the CNS during development and disease: insights from <i>in vivo</i> and <i>in vitro</i> models. | Buchsbaum IY et al. | β | 2019 | β |
| Nicotine prevents alpha-synuclein accumulation in mouse and human iPSC-derived dopaminergic neurons through activation of the dopamine D3- acetylcholine nicotinic receptor heteromer. | Bono F et al. | β | 2019 | β |
| Optogenetically transduced human ES cell-derived neural progenitors and their neuronal progenies: Phenotypic characterization and responses to optical stimulation. | Ryu J et al. | β | 2019 | β |
| Patient-Specific iPSC-Derived Astrocytes Contribute to Non-Cell-Autonomous Neurodegeneration in Parkinson's Disease. | di Domenico A et al. | β | 2019 | β |
| Patient-specific pluripotent stem cell-based Parkinson's disease models showing endogenous alpha-synuclein aggregation. | Oh Y | β | 2019 | β |
| Peripheral Delivery of Neural Precursor Cells Ameliorates Parkinson's Disease-Associated Pathology. | Edwards Iii G et al. | β | 2019 | β |
| Pharmacological Transdifferentiation of Human Nasal Olfactory Stem Cells into Dopaminergic Neurons. | Chabrat A et al. | β | 2019 | β |
| Preparation and Co-Culture of iPSC-Derived Dopaminergic Neurons and Astrocytes. | de Rus Jacquet A | β | 2019 | β |
| Primate stem cells: bridge the translation from basic research to clinic application. | Li T et al. | β | 2019 | β |
| Reconstitution of the Human Nigro-striatal Pathway on-a-Chip Reveals OPA1-Dependent Mitochondrial Defects and Loss of Dopaminergic Synapses. | Iannielli A et al. | β | 2019 | β |
| Regenerative medicine: could Parkinson's be the first neurodegenerative disease to be cured? | DΓaz ML | β | 2019 | β |
| RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes. | Booth HDE et al. | β | 2019 | β |
| Seeding Induced Pluripotent Stem Cell-Derived Neurons onto 384-Well Plates. | Little D et al. | β | 2019 | β |
| Single Cell Gene Expression Analysis Reveals Human Stem Cell-Derived Graft Composition in a Cell Therapy Model of Parkinsonβs Disease | TiklovΓ‘ K et al. | β | 2019 | β |
| Single-Cell Sequencing of iPSC-Dopamine Neurons Reconstructs Disease Progression and Identifies HDAC4 as a Regulator of Parkinson Cell Phenotypes. | Lang C et al. | β | 2019 | β |
| SOX21 Ensures Rostral Forebrain Identity by Suppression of WNT8B during Neural Regionalization of Human Embryonic Stem Cells. | Fang Z et al. | β | 2019 | β |
| Stem cell-based therapy for Parkinson's disease with a focus on human endometrium-derived mesenchymal stem cells. | Bagheri-Mohammadi S et al. | β | 2019 | β |
| Stem cell therapy for neurological disorders: A focus on aging. | Nguyen H et al. | β | 2019 | β |
| Stress-Induced Cellular Clearance Is Mediated by the SNARE Protein ykt6 and Disrupted by Ξ±-Synuclein. | Cuddy LK et al. | β | 2019 | β |
| Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. | Logan S et al. | β | 2019 | β |
| Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. | Xue Y et al. | β | 2019 | β |
| Task Force Paper On Cerebellar Transplantation: Are We Ready to Treat Cerebellar Disorders with Cell Therapy? | Cendelin J et al. | β | 2019 | β |
| The Substantia Nigra Is Permissive and Gains Inductive Signals When Lesioned for Dopaminergic Differentiation of Embryonic Stem Cells. | Collazo-Navarrete O et al. | β | 2019 | β |
| Transcriptional Profiling of Xenogeneic Transplants: Examining Human Pluripotent Stem Cell-Derived Grafts in the Rodent Brain. | Bye CR et al. | β | 2019 | β |
| Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders. | Mohammadi A et al. | β | 2019 | β |
| Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells. | Stoddard-Bennett T et al. | β | 2019 | β |
| Uses for humanised mouse models in precision medicine for neurodegenerative disease. | Nair RR et al. | β | 2019 | β |
| Using human stem cells as a model system to understand the neural mechanisms of alcohol use disorders: Current status and outlook. | Scarnati MS et al. | β | 2019 | β |
| Using induced pluripotent stem cells for modeling Parkinson's disease. | Ke M et al. | β | 2019 | β |
| Xeno-free and feeder-free culture and differentiation of human embryonic stem cells on recombinant vitronectin-grafted hydrogels. | Chen LH et al. | β | 2019 | β |
| (2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans. | Collo G et al. | β | 2018 | β |
| Acid ceramidase inhibition ameliorates Ξ±-synuclein accumulation upon loss of GBA1 function. | Kim MJ et al. | β | 2018 | β |
| A Combination of NT-4/5 and GDNF Is Favorable for Cultured Human Nigral Neural Progenitor Cells. | Di Santo S et al. | β | 2018 | β |
| A Comparative Study of the Effects of Sodium Selenite and Glutathione Mono Ethyl Ester on Aged Adipose-Derived Stem Cells: The Telomerase and Cellular Responses. | Aminizadeh N et al. | β | 2018 | β |
| Acquired Genetic and Epigenetic Variation in Human Pluripotent Stem Cells. | Kyriakides O et al. | β | 2018 | β |
| Adherent vs. Free-Floating Neural Induction by Dual SMAD Inhibition for Neurosphere Cultures Derived from Human Induced Pluripotent Stem Cells. | Pauly MG et al. | β | 2018 | β |
| Adipose-derived Stem Cells Stimulated with n-Butylidenephthalide Exhibit Therapeutic Effects in a Mouse Model of Parkinson's Disease. | Chi K et al. | β | 2018 | β |
| Aging in a Dish: iPSC-Derived and Directly Induced Neurons for Studying Brain Aging and Age-Related Neurodegenerative Diseases. | Mertens J et al. | β | 2018 | β |
| A hPSC-based platform to discover gene-environment interactions that impact human Ξ²-cell and dopamine neuron survival. | Zhou T et al. | β | 2018 | β |
| Alpha6-Containing Nicotinic Acetylcholine Receptors Mediate Nicotine-Induced Structural Plasticity in Mouse and Human iPSC-Derived Dopaminergic Neurons. | Collo G et al. | β | 2018 | β |
| An in vivo model of functional and vascularized human brain organoids. | Mansour AA et al. | β | 2018 | β |
| An update on intracerebral stem cell grafts. | Neal EG et al. | β | 2018 | β |
| A single cell high content assay detects mitochondrial dysfunction in iPSC-derived neurons with mutations in SNCA. | Little D et al. | β | 2018 | β |
| A stably self-renewing adult blood-derived induced neural stem cell exhibiting patternability and epigenetic rejuvenation. | Sheng C et al. | β | 2018 | β |
| Astrocytes Attenuate Mitochondrial Dysfunctions in Human Dopaminergic Neurons Derived from iPSC. | Du F et al. | β | 2018 | β |
| BMP/SMAD Pathway Promotes Neurogenesis of Midbrain Dopaminergic Neurons <i>In Vivo</i> and in Human Induced Pluripotent and Neural Stem Cells. | Jovanovic VM et al. | β | 2018 | β |
| Building Models of Brain Disorders with Three-Dimensional Organoids. | Amin ND et al. | β | 2018 | β |
| Cardiolipin exposure onΒ the outer mitochondrial membrane modulates Ξ±-synuclein. | Ryan T et al. | β | 2018 | β |
| Cell-Biological Requirements for the Generation of Dentate Gyrus Granule Neurons. | Hatami M et al. | β | 2018 | β |
| Cell-Type-Specific Proteomics: A Neuroscience Perspective. | Wilson RS et al. | β | 2018 | β |
| Cografting astrocytes improves cell therapeutic outcomes in a Parkinson's disease model. | Song JJ et al. | β | 2018 | β |
| Combinatorial programming of human neuronal progenitors using magnetically-guided stoichiometric mRNA delivery. | Azimi SM et al. | β | 2018 | β |
| Concise Review: The Cellular Conspiracy of Amyotrophic Lateral Sclerosis. | Serio A et al. | β | 2018 | β |
| Current Perspectives regarding Stem Cell-Based Therapy for Alzheimer's Disease. | Kwak KA et al. | β | 2018 | β |
| Developing defined substrates for stem cell culture and differentiation. | Hagbard L et al. | β | 2018 | β |
| Directing neuronal cell fate in vitro: Achievements and challenges. | Riemens RJM et al. | β | 2018 | β |
| Discovery of Novel Cell Surface Markers for Purification of Embryonic Dopamine Progenitors for Transplantation in Parkinson's Disease Animal Models. | Fathi A et al. | β | 2018 | β |
| Dynamic Changes of the Mitochondria in Psychiatric Illnesses: New Mechanistic Insights From Human Neuronal Models. | Srivastava R et al. | β | 2018 | β |
| Effects of Passage Number and Differentiation Protocol on the Generation of Dopaminergic Neurons from Rat Bone Marrow-Derived Mesenchymal Stem Cells. | Shall G et al. | β | 2018 | β |
| Emerging Treatment Approaches for Parkinson's Disease. | Stoker TB et al. | β | 2018 | β |
| Ferritin nanoparticles for improved self-renewal and differentiation of human neural stem cells. | Lee JS et al. | β | 2018 | β |
| Fine Tuning of Canonical Wnt Stimulation Enhances Differentiation of Pluripotent Stem Cells Independent of Ξ²-Catenin-Mediated T-Cell Factor Signaling. | Chen J et al. | β | 2018 | β |
| Generation of defined neural populations from pluripotent stem cells. | McComish SF et al. | β | 2018 | β |
| Generation of dopamine neuronal-like cells from induced neural precursors derived from adult human cells by non-viral expression of lineage factors. | Playne R et al. | β | 2018 | β |
| Generation of human brain region-specific organoids using a miniaturized spinning bioreactor. | Qian X et al. | β | 2018 | β |
| Guggulsterone-releasing microspheres direct the differentiation of human induced pluripotent stem cells into neural phenotypes. | Agbay A et al. | β | 2018 | β |
| How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. | Ioannidis JPA et al. | β | 2018 | β |
| hPSC-Derived Striatal Cells Generated Using a Scalable 3D Hydrogel Promote Recovery in a Huntington Disease Mouse Model. | Adil MM et al. | β | 2018 | β |
| HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. | Kishinevsky S et al. | β | 2018 | β |
| Human Clinical-Grade Parthenogenetic ESC-Derived Dopaminergic NeuronsΒ Recover Locomotive Defects of Nonhuman Primate Models ofΒ Parkinson's Disease. | Wang YK et al. | β | 2018 | β |
| Human embryonic stem cell dispersion in electrospun PCL fiber scaffolds by coating with laminin-521 and E-cadherin-Fc. | Leino M et al. | β | 2018 | β |
| Human neurons to model aging: A dish best served old. | BΓΆhnke L et al. | β | 2018 | β |
| Hydrogel-Based Bioprocess for Scalable Manufacturing of Human Pluripotent Stem Cell-Derived Neural Stem Cells. | Lin H et al. | β | 2018 | β |
| Induced Pluripotent Stem Cells: A Powerful Neurodegenerative Disease Modeling Tool for Mechanism Study and Drug Discovery. | Chang CY et al. | β | 2018 | β |
| Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism. | Jung-Klawitter S et al. | β | 2018 | β |
| Influencing the Fate of Cardiac and Neural Stem Cell Differentiation Using Small Molecule Inhibitors of ALK5. | Zhong Q et al. | β | 2018 | β |
| Internalization, axonal transport and release of fibrillar forms of alpha-synuclein. | Bieri G et al. | β | 2018 | β |
| iPS cells in the study of PD molecular pathogenesis. | Cobb MM et al. | β | 2018 | β |
| Iron overload is accompanied by mitochondrial and lysosomal dysfunction in WDR45 mutant cells. | Seibler P et al. | β | 2018 | β |
| Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling. | Cavalleri L et al. | β | 2018 | β |
| LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease. | Nguyen M et al. | β | 2018 | β |
| Mapping human pluripotent stem cell differentiation pathways using high throughput single-cell RNA-sequencing. | Han X et al. | β | 2018 | β |
| MicroRNA profiling during directed differentiation of cortical interneurons from human-induced pluripotent stem cells. | Tu J et al. | β | 2018 | β |
| Migratory potential of transplanted glial progenitors as critical factor for successful translation of glia replacement therapy: The gap between mice and men. | Srivastava RK et al. | β | 2018 | β |
| Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy. | Monzio Compagnoni G et al. | β | 2018 | β |
| Modeling Neuropsychiatric and Neurodegenerative Diseases With Induced Pluripotent Stem Cells. | LaMarca EA et al. | β | 2018 | β |
| Nature Biotechnology's academic spinouts of 2017. | Branca MA et al. | β | 2018 | β |
| Neural stem cell therapy-Brief review. | Grochowski C et al. | β | 2018 | β |
| Neurotrophic factor-based strategies to enhance survival and differentiation of neural progenitor cells toward the dopaminergic phenotype. | Di Santo S et al. | β | 2018 | β |
| Nitration of microtubules blocks axonal mitochondrial transport in a human pluripotent stem cell model of Parkinson's disease. | Stykel MG et al. | β | 2018 | β |
| Non-human primate models of PD to test novel therapies. | Morissette M et al. | β | 2018 | β |
| Novel Approach to Stem Cell Therapy in Parkinson's Disease. | Garitaonandia I et al. | β | 2018 | β |
| Open chromatin dynamics reveals stage-specific transcriptional networks in hiPSC-based neurodevelopmental model. | Zhang S et al. | β | 2018 | β |
| Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders. | Han C et al. | β | 2018 | β |
| Parkinson's disease: what the model systems have taught us so far. | Ghatak S et al. | β | 2018 | β |
| Patient-Derived Induced Pluripotent Stem Cells and Organoids for Modeling Alpha Synuclein Propagation in Parkinson's Disease. | Koh YH et al. | β | 2018 | β |
| Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. | Sonntag KC et al. | β | 2018 | β |
| Pluripotent Stem Cells for Modelling and Cell Therapy of Parkinson's Disease. | Lebedeva OS et al. | β | 2018 | β |
| Recent advances in stem cells therapy: A focus on cancer, Parkinson's and Alzheimer's. | Fleifel D et al. | β | 2018 | β |
| Repairing the Brain: Cell Replacement Using Stem Cell-Based Technologies. | Henchcliffe C et al. | β | 2018 | β |
| Reversible Conformational Conversion of Ξ±-Synuclein into Toxic Assemblies by Glucosylceramide. | Zunke F et al. | β | 2018 | β |
| Robust and High Spatial Resolution Light Addressable Electrochemistry Using Hematite (Ξ±-Fe<sub>2</sub>O<sub>3</sub>) Photoanodes. | Seo D et al. | β | 2018 | β |
| Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. | Bono F et al. | β | 2018 | β |
| Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. | Collo G et al. | β | 2018 | β |
| Safranal-promoted differentiation and survival of dopaminergic neurons in an animal model of Parkinson's disease. | Zhao Y et al. | β | 2018 | β |
| Sequential Application of Discrete Topographical Patterns Enhances Derivation of Functional Mesencephalic Dopaminergic Neurons from Human Induced Pluripotent Stem Cells. | Tan KKB et al. | β | 2018 | β |
| Signaling-Dependent Control of Apical Membrane Size and Self-Renewal in Rosette-Stage Human Neuroepithelial Stem Cells. | Medelnik JP et al. | β | 2018 | β |
| Single-cell genomics to guide human stem cell and tissue engineering. | Camp JG et al. | β | 2018 | β |
| Single-cell RNA-seq reveals dynamic transcriptome profiling in human early neural differentiation. | Shang Z et al. | β | 2018 | β |
| Single-injection ex ovo transplantation method for broad spinal cord engraftment of human pluripotent stem cell-derived motor neurons. | Estevez-Silva MC et al. | β | 2018 | β |
| Standards for Deriving Nonhuman Primate-Induced Pluripotent Stem Cells, Neural Stem Cells and Dopaminergic Lineage. | Yang G et al. | β | 2018 | β |
| Stem cell modeling of mitochondrial parkinsonism reveals key functions of OPA1. | Jonikas M et al. | β | 2018 | β |
| Stem cells and regenerative medicine for neural repair. | Takahashi J | β | 2018 | β |
| Suspended graphene oxide nanosheets maintain the self-renewal of mouse embryonic stem cells via down-regulating the expression of Vinculin. | Jing G et al. | β | 2018 | β |
| Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models. | Taoufik E et al. | β | 2018 | β |
| Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology. | Wang C et al. | β | 2018 | β |
| Target-specific forebrain projections and appropriate synaptic inputs of hESC-derived dopamine neurons grafted to the midbrain of parkinsonian rats. | Cardoso T et al. | β | 2018 | β |
| TGFΞ² signaling hyperactivation-induced tumorigenicity during the derivation of neural progenitors from mouse ESCs. | Yang X et al. | β | 2018 | β |
| The Matricellular Protein R-Spondin 2 Promotes Midbrain Dopaminergic Neurogenesis and Differentiation. | Gyllborg D et al. | β | 2018 | β |
| The rise of three-dimensional human brain cultures. | PaΘca SP | β | 2018 | β |
| Thermoreversible Hyaluronic Acid-PNIPAAm Hydrogel Systems for 3D Stem Cell Culture. | Ekerdt BL et al. | β | 2018 | β |
| The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease. | Vermilyea SC et al. | β | 2018 | β |
| The state of the art in stem cell biology and regenerative medicine: the end of the beginning. | Snyder EY | β | 2018 | β |
| The telomerase inhibitor AZT enhances differentiation and prevents overgrowth of human pluripotent stem cell-derived neural progenitors. | Hu Y et al. | β | 2018 | β |
| Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease. | Struzyna LA et al. | β | 2018 | β |
| Towards better cellular replacement therapies in Parkinson disease. | Sun AX et al. | β | 2018 | β |
| Towards stem cell based therapies for Parkinson's disease. | Parmar M | β | 2018 | β |
| Transcriptional landscape of a RET<sup>C634Y</sup>-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers. | Hadoux J et al. | β | 2018 | β |
| Using intracellular markers to identify a novel set of surface markers for live cell purification from a heterogeneous hIPSC culture. | Paik EJ et al. | β | 2018 | β |
| Wnt signal activation induces midbrain specification through direct binding of the beta-catenin/TCF4 complex to the EN1 promoter in human pluripotent stem cells. | Kim JY et al. | β | 2018 | β |
| Wnt/Ξ²-Catenin Signaling Pathway Governs a Full Program for Dopaminergic Neuron Survival, Neurorescue and Regeneration in the MPTP Mouse Model of Parkinson's Disease. | Marchetti B | β | 2018 | β |
| 2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease. | Niu J et al. | β | 2017 | β |
| Accreditation of Biosafe Clinical-Grade Human Embryonic Stem Cells According to Chinese Regulations. | Gu Q et al. | β | 2017 | β |
| A Knockin Reporter Allows Purification and Characterization of mDA Neurons from Heterogeneous Populations. | Xia N et al. | β | 2017 | β |
| Altered Differentiation Potential of Gaucher's Disease iPSC Neuronal Progenitors due to Wnt/Ξ²-Catenin Downregulation. | Awad O et al. | β | 2017 | β |
| An Integrated Miniature Bioprocessing for Personalized Human Induced Pluripotent Stem Cell Expansion and Differentiation into Neural Stem Cells. | Lin H et al. | β | 2017 | β |
| A novel floor plate boundary defined by adjacent En1 and Dbx1 microdomains distinguishes midbrain dopamine and hypothalamic neurons. | Nouri N et al. | β | 2017 | β |
| A PITX3-EGFP Reporter Line Reveals Connectivity of Dopamine and Non-dopamine Neuronal Subtypes in Grafts Generated from Human Embryonic Stem Cells. | Niclis JC et al. | β | 2017 | β |
| Application of induced pluripotent stem cells to understand neurobiological basis of bipolar disorder and schizophrenia. | Liu YN et al. | β | 2017 | β |
| A Rapid Pipeline to Model Rare Neurodevelopmental Disorders with Simultaneous CRISPR/Cas9 Gene Editing. | Bell S et al. | β | 2017 | β |
| A Rationally Designed, General Strategy for Membrane Orientation of Photoinduced Electron Transfer-Based Voltage-Sensitive Dyes. | Kulkarni RU et al. | β | 2017 | β |
| Are reprogrammed cells a useful tool for studying dopamine dysfunction in psychotic disorders? A review of the current evidence. | Sauerzopf U et al. | β | 2017 | β |
| A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease. | Hazelbaker DZ et al. | β | 2017 | β |
| Astrocytes in a dish: Using pluripotent stem cells to model neurodegenerative and neurodevelopmental disorders. | Crompton LA et al. | β | 2017 | β |
| A Subpopulation of Dopaminergic Neurons Coexpresses Serotonin in Ventral Mesencephalic Cultures But Not After Intrastriatal Transplantation in a Rat Model of Parkinson's Disease. | Di Santo S et al. | β | 2017 | β |
| A xenogeneic-free system generating functional human gut organoids from pluripotent stem cells. | Uchida H et al. | β | 2017 | β |
| Bringing Neural Cell Therapies to the Clinic: Past and Future Strategies. | Irion S et al. | β | 2017 | β |
| C9ORF135 encodes a membrane protein whose expression is related to pluripotency in human embryonic stem cells. | Zhou S et al. | β | 2017 | β |
| Cardiolipin promotes electron transport between ubiquinone and complex I to rescue <i>PINK1</i> deficiency. | Vos M et al. | β | 2017 | β |
| Cell reprogramming: Therapeutic potential and the promise of rejuvenation for the aging brain. | LΓ³pez-LeΓ³n M et al. | β | 2017 | β |
| Characterising the developmental profile of human embryonic stem cell-derived medium spiny neuron progenitors and assessing mature neuron function using a CRISPR-generated human DARPP-32<sup>WT/eGFP-AMP</sup> reporter line. | Hunt CPJ et al. | β | 2017 | β |
| Combined small-molecule inhibition accelerates the derivation of functional cortical neurons from human pluripotent stem cells. | Qi Y et al. | β | 2017 | β |
| Concise Review: Induced Pluripotent Stem Cell Models for Neuropsychiatric Diseases. | Adegbola A et al. | β | 2017 | β |
| Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular Reprogramming. | Ruetz T et al. | β | 2017 | β |
| Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes InΒ Vivo. | Wakeman DR et al. | β | 2017 | β |
| Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons. | Schwab AJ et al. | β | 2017 | β |
| Delayed Accumulation of H3K27me3 on Nascent DNA Is Essential for Recruitment of Transcription Factors at Early Stages of Stem Cell Differentiation. | Petruk S et al. | β | 2017 | β |
| Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases. | Serafino A et al. | β | 2017 | β |
| Developing HiPSC Derived Serum Free Embryoid Bodies for the Interrogation of 3-D Stem Cell Cultures Using Physiologically Relevant Assays. | Phillips AW et al. | β | 2017 | β |
| Directed Differentiation of Human Embryonic Stem Cells Toward Placode-Derived Spiral Ganglion-Like Sensory Neurons. | Matsuoka AJ et al. | β | 2017 | β |
| Directed Differentiation of Mouse Embryonic Stem Cells Into Inner Ear Sensory Epithelia in 3D Culture. | Nie J et al. | β | 2017 | β |
| Direct induction of functional neuronal cells from fibroblast-like cells derived from adult human retina. | Hao L et al. | β | 2017 | β |
| Direct Reprogramming of Fibroblasts via a Chemically Induced XEN-like State. | Li X et al. | β | 2017 | β |
| Direct Reprogramming Rather than iPSC-Based Reprogramming Maintains Aging Hallmarks in Human Motor Neurons. | Tang Y et al. | β | 2017 | β |
| Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. | Burbulla LF et al. | β | 2017 | β |
| Effect of Wnt1 and Wnt5a on the development of dopaminergic neurons, and toxicity induced by combined exposure to paraquat and maneb during gestation and lactation. | Ma J et al. | β | 2017 | β |
| Efficient Generation of Dopamine Neurons by Synthetic Transcription Factor mRNAs. | Kim SM et al. | β | 2017 | β |
| Efficient generation of hPSC-derived midbrain dopaminergic neurons in a fully defined, scalable, 3D biomaterial platform. | Adil MM et al. | β | 2017 | β |
| Efficiently Specified Ventral Midbrain Dopamine Neurons from Human Pluripotent Stem Cells Under Xeno-Free Conditions Restore Motor Deficits in Parkinsonian Rodents. | Niclis JC et al. | β | 2017 | β |
| Engineered hydrogels increase the post-transplantation survival of encapsulated hESC-derived midbrain dopaminergic neurons. | Adil MM et al. | β | 2017 | β |
| Engineering-derived approaches for iPSC preparation, expansion, differentiation and applications. | Li Y et al. | β | 2017 | β |
| Enhanced derivation of human pluripotent stem cell-derived cortical glutamatergic neurons by a small molecule. | Cao SY et al. | β | 2017 | β |
| Escape from Pluripotency via Inhibition of TGF-Ξ²/BMP and Activation of Wnt Signaling Accelerates Differentiation and Aging in hPSC Progeny Cells. | Fujimori K et al. | β | 2017 | β |
| Expansion and Purification Are Critical for the Therapeutic Application of Pluripotent Stem Cell-Derived Myogenic Progenitors. | Kim J et al. | β | 2017 | β |
| Expansion of human midbrain floor plate progenitors from induced pluripotent stem cells increases dopaminergic neuron differentiation potential. | Fedele S et al. | β | 2017 | β |
| Exploring pre-degenerative alterations in humans using induced pluripotent stem cell-derived dopaminergic neurons. | Bono F et al. | β | 2017 | β |
| FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson's disease. | Guo X et al. | β | 2017 | β |
| From stem cells to human development: a distinctly human perspective on early embryology, cellular differentiation and translational research. | Craft AM et al. | β | 2017 | β |
| From the Cover: Manganese and Rotenone-Induced Oxidative Stress Signatures Differ in iPSC-Derived Human Dopamine Neurons. | Neely MD et al. | β | 2017 | β |
| Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. | Nolbrant S et al. | β | 2017 | β |
| Generation of inner ear organoids containing functional hair cells from human pluripotent stem cells. | Koehler KR et al. | β | 2017 | β |
| Genetic Rescue of Mitochondrial and Skeletal Muscle Impairment in an Induced Pluripotent Stem Cells Model of Coenzyme Q<sub>10</sub> Deficiency. | Romero-Moya D et al. | β | 2017 | β |
| Genome-Scale Networks Link Neurodegenerative Disease Genes to Ξ±-Synuclein through Specific Molecular Pathways. | Khurana V et al. | β | 2017 | β |
| Genome-wide prediction of DNase I hypersensitivity using gene expression. | Zhou W et al. | β | 2017 | β |
| Gold nanoparticles enhance the differentiation of embryonic stem cells into dopaminergic neurons via mTOR/p70S6K pathway. | Wei M et al. | β | 2017 | β |
| Human Cerebrospinal fluid promotes long-term neuronal viability and network function in human neocortical organotypic brain slice cultures. | Schwarz N et al. | β | 2017 | β |
| Human induced pluripotent stem cells for modelling neurodevelopmental disorders. | Ardhanareeswaran K et al. | β | 2017 | β |
| Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. | Kikuchi T et al. | β | 2017 | β |
| Human polymorphisms in nicotinic receptors: a functional analysis in iPS-derived dopaminergic neurons. | Deflorio C et al. | β | 2017 | β |
| Human Trials of Stem Cell-Derived Dopamine Neurons for Parkinson's Disease: Dawn of a New Era. | Barker RA et al. | β | 2017 | β |
| IAP-Based Cell Sorting Results in Homogeneous Transplantable Dopaminergic Precursor Cells Derived from Human Pluripotent Stem Cells. | Lehnen D et al. | β | 2017 | β |
| Idiopathic Parkinson's disease patient-derived induced pluripotent stem cells function as midbrain dopaminergic neurons in rodent brains. | Kikuchi T et al. | β | 2017 | β |
| Immature Midbrain Dopaminergic Neurons Derived from Floor-Plate Method Improve Cell Transplantation Therapy Efficacy for Parkinson's Disease. | Qiu L et al. | β | 2017 | β |
| Induced Pluripotent Stem Cell Neuronal Models for the Study of Autophagy Pathways in Human Neurodegenerative Disease. | JimΓ©nez-Moreno N et al. | β | 2017 | β |
| Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model. | Rivetti di Val Cervo P et al. | β | 2017 | β |
| Long-Distance Axonal Growth and Protracted Functional Maturation of Neurons Derived from Human Induced Pluripotent Stem Cells After Intracerebral Transplantation. | Niclis JC et al. | β | 2017 | β |
| MAPT Genetic Variation and Neuronal Maturity Alter Isoform Expression Affecting Axonal Transport in iPSC-Derived Dopamine Neurons. | Beevers JE et al. | β | 2017 | β |
| Mechanisms and use of neural transplants for brain repair. | Dunnett SB et al. | β | 2017 | β |
| Melatonin enhances neural stem cell differentiation and engraftment by increasing mitochondrial function. | Mendivil-Perez M et al. | β | 2017 | β |
| Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models. | Lopes FM et al. | β | 2017 | β |
| Modeling neurodevelopmental and psychiatric diseases with human iPSCs. | Wen Z | β | 2017 | β |
| Modeling Parkinson's disease with induced pluripotent stem cells harboring Ξ±-synuclein mutations. | Singh Dolt K et al. | β | 2017 | β |
| MYC Controls Human Pluripotent Stem Cell Fate Decisions through Regulation of Metabolic Flux. | Cliff TS et al. | β | 2017 | β |
| Neural grafting for Parkinson's disease: challenges and prospects. | Stoker TB et al. | β | 2017 | β |
| Neural organoids for disease phenotyping, drug screening and developmental biology studies. | Hartley BJ et al. | β | 2017 | β |
| Neuronal replacement therapy: previous achievements and challenges ahead. | Grade S et al. | β | 2017 | β |
| Neurotoxic reactive astrocytes are induced by activated microglia. | Liddelow SA et al. | β | 2017 | β |
| Optogenetics and its application in neural degeneration and regeneration. | Ordaz JD et al. | β | 2017 | β |
| Pluripotent stem cell-derived neurons for transplantation in Huntington's disease. | Li M et al. | β | 2017 | β |
| Pluripotent stem cells in neuropsychiatric disorders. | Soliman MA et al. | β | 2017 | β |
| Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo. | Moon J et al. | β | 2017 | β |
| Predictive Markers Guide Differentiation to Improve Graft Outcome in Clinical Translation of hESC-Based Therapy for Parkinson's Disease. | Kirkeby A et al. | β | 2017 | β |
| Preparation, characterization, and banking of clinical-grade cells for neural transplantation: Scale up, fingerprinting, and genomic stability of stem cell lines. | Natalwala A et al. | β | 2017 | β |
| Purification and characterization of chondroitinase ABC from Acinetobacter sp. C26. | Zhu C et al. | β | 2017 | β |
| Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors. | Carelli S et al. | β | 2017 | β |
| Replacing Dopamine Neurons inΒ Parkinson's Disease: How did it happen? | BjΓΆrklund A et al. | β | 2017 | β |
| Seq-ing Markers of Midbrain Dopamine Neurons. | Osborn T et al. | β | 2017 | β |
| Single-Cell Analysis Reveals a Close Relationship between Differentiating Dopamine and Subthalamic Nucleus Neuronal Lineages. | Kee N et al. | β | 2017 | β |
| SLP-2 interacts with Parkin in mitochondria and prevents mitochondrial dysfunction in Parkin-deficient human iPSC-derived neurons and Drosophila. | Zanon A et al. | β | 2017 | β |
| Species-specific developmental timing is maintained by pluripotent stem cells ex utero. | Barry C et al. | β | 2017 | β |
| Specification of murine ground state pluripotent stem cells to regional neuronal populations. | Alsanie WF et al. | β | 2017 | β |
| Stem Cells for Modeling and Therapy of Parkinson's Disease. | Zhang Q et al. | β | 2017 | β |
| Stem Cell Therapies for Reversing Vision Loss. | Higuchi A et al. | β | 2017 | β |
| Strategies for bringing stem cell-derived dopamine neurons to the clinic: A European approach (STEM-PD). | Kirkeby A et al. | β | 2017 | β |
| Strategies for bringing stem cell-derived dopamine neurons to the clinic: The Kyoto trial. | Takahashi J | β | 2017 | β |
| Strategies for bringing stem cell-derived dopamine neurons to the clinic-The NYSTEM trial. | Studer L | β | 2017 | β |
| Targeting sonic hedgehog signaling in neurological disorders. | Patel SS et al. | β | 2017 | β |
| The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. | Straniero L et al. | β | 2017 | β |
| The Multiple Roles of FGF Signaling in the Developing Spinal Cord. | Diez Del Corral R et al. | β | 2017 | β |
| Therapeutic Potential of Induced Neural Stem Cells for Parkinson's Disease. | Choi DH et al. | β | 2017 | β |
| The science and ethics of cell-based therapies for Parkinson's disease. | Towns CR | β | 2017 | β |
| The shedding protease ADAM17: Physiology and pathophysiology. | Zunke F et al. | β | 2017 | β |
| The translational potential of humanΒ induced pluripotent stem cells for clinical neurology : The translational potential of hiPSCs in neurology. | Devine H et al. | β | 2017 | β |
| Three-dimensional tissues using human pluripotent stem cell spheroids as biofabrication building blocks. | Lin H et al. | β | 2017 | β |
| Toward the human cellular microRNAome. | McCall MN et al. | β | 2017 | β |
| Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease. | Sandor C et al. | β | 2017 | β |
| Translation of WNT developmental programs into stem cell replacement strategies for the treatment of Parkinson's disease. | Toledo EM et al. | β | 2017 | β |
| Transplantation in the nonhuman primate MPTP model of Parkinson's disease: update and perspectives. | Wianny F et al. | β | 2017 | β |
| Two sides of the same coin? Unraveling subtle differences between human embryonic and induced pluripotent stem cells by Raman spectroscopy. | Parrotta E et al. | β | 2017 | β |
| Understanding neurodevelopmental disorders using human pluripotent stem cell-derived neurons. | Tamburini C et al. | β | 2017 | β |
| Understanding Parkinson's Disease through the Use of Cell Reprogramming. | Playne R et al. | β | 2017 | β |
| Vitamin C-Induced Epigenetic Modifications in Donor NSCs Establish Midbrain Marker Expressions Critical for Cell-Based Therapy in Parkinson's Disease. | Wulansari N et al. | β | 2017 | β |
| Wnt/Ξ²-catenin signaling during early vertebrate neural development. | Brafman D et al. | β | 2017 | β |
| Xeno-free culture of human pluripotent stem cells on oligopeptide-grafted hydrogels with various molecular designs. | Chen YM et al. | β | 2017 | β |
| A Compendium of Preparation and Application of Stem Cells in Parkinson's Disease: Current Status and Future Prospects. | Shen Y et al. | β | 2016 | β |
| Activation of Ξ²-Glucocerebrosidase Reduces Pathological Ξ±-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons. | Mazzulli JR et al. | β | 2016 | β |
| Adapting Preclinical Benchmarks for First-in-Human Trials of Human Embryonic Stem Cell-Based Therapies. | Barazzetti G et al. | β | 2016 | β |
| Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease. | Grow DA et al. | β | 2016 | β |
| A New Glucocerebrosidase Chaperone Reduces Ξ±-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. | Aflaki E et al. | β | 2016 | β |
| A PBX1 transcriptional network controls dopaminergic neuron development and is impaired in Parkinson's disease. | Villaescusa JC et al. | β | 2016 | β |
| At the interface of stem cell research and new technologies. | Lendahl U | β | 2016 | β |
| Brain repair and reprogramming: the route to clinical translation. | Grealish S et al. | β | 2016 | β |
| Cell therapies for Parkinson's disease: how far have we come? | Stoker TB et al. | β | 2016 | β |
| Chemical Modulation of Cell Fate in Stem Cell Therapeutics and Regenerative Medicine. | Liu K et al. | β | 2016 | β |
| Common pitfalls of stem cell differentiation: a guide to improving protocols for neurodegenerative disease models and research. | Engel M et al. | β | 2016 | β |
| Creation of a library of induced pluripotent stem cells from Parkinsonian patients. | Holmqvist S et al. | β | 2016 | β |
| CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish. | GonzΓ‘lez F | β | 2016 | β |
| Differentiation and Characterization of Dopaminergic Neurons From Baboon Induced Pluripotent Stem Cells. | Grow DA et al. | β | 2016 | β |
| Differentiation of Human Embryonic Stem Cells to Endothelial Progenitor Cells on Laminins in Defined and Xeno-free Systems. | Nguyen MTX et al. | β | 2016 | β |
| Direct neuronal reprogramming: learning from and for development. | Masserdotti G et al. | β | 2016 | β |
| Dopamine Receptor Antagonists Enhance Proliferation and Neurogenesis of Midbrain Lmx1a-expressing Progenitors. | Hedlund E et al. | β | 2016 | β |
| DREADD Modulation of Transplanted DA Neurons Reveals a Novel Parkinsonian Dyskinesia Mechanism Mediated by the Serotonin 5-HT6 Receptor. | Aldrin-Kirk P et al. | β | 2016 | β |
| Effects of Feeder Cells on Dopaminergic Differentiation of Human Embryonic Stem Cells. | Zhao Z et al. | β | 2016 | β |
| Efficient generation of dopaminergic-like neurons by overexpression of Nurr1 and Pitx3 in mouse induced Pluripotent Stem Cells. | Salemi S et al. | β | 2016 | β |
| Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience. | Mertens J et al. | β | 2016 | β |
| Fail-Safe Therapy by Gamma-Ray Irradiation Against Tumor Formation by Human-Induced Pluripotent Stem Cell-Derived Neural Progenitors. | Katsukawa M et al. | β | 2016 | β |
| FolR1: a novel cell surface marker for isolating midbrain dopamine neural progenitors and nascent dopamine neurons. | Gennet N et al. | β | 2016 | β |
| GAPTrap: A Simple Expression System for Pluripotent Stem Cells and Their Derivatives. | Kao T et al. | β | 2016 | β |
| Generating Late-Onset Human iPSC-Based Disease Models by Inducing Neuronal Age-Related Phenotypes through Telomerase Manipulation. | Vera E et al. | β | 2016 | β |
| Generating long-lived CD8(+) T-cell memory: Insights from epigenetic programs. | Dogra P et al. | β | 2016 | β |
| Generation of Cholinergic and Dopaminergic Interneurons from Human Pluripotent Stem Cells as a Relevant Tool for In Vitro Modeling of Neurological Disorders Pathology and Therapy. | Ochalek A et al. | β | 2016 | β |
| Generation of Human Corneal Endothelial Cells via In Vitro Ocular Lineage Restriction of Pluripotent Stem Cells. | Zhao JJ et al. | β | 2016 | β |
| Genetic and pharmacological correction of aberrant dopamine synthesis using patient iPSCs with BH4 metabolism disorders. | Ishikawa T et al. | β | 2016 | β |
| Grafted Neural Precursors Integrate Into Mouse Striatum, Differentiate and Promote Recovery of Function Through Release of Erythropoietin in MPTP-Treated Mice. | Carelli S et al. | β | 2016 | β |
| hESC-derived neural progenitors prevent xenograft rejection through neonatal desensitisation. | Heuer A et al. | β | 2016 | β |
| Human Neural Tissue Construct Fabrication Based on Scaffold-Free Tissue Engineering. | Takahashi H et al. | β | 2016 | β |
| Increased nicotine response in iPSC-derived human neurons carrying the CHRNA5 N398 allele. | Oni EN et al. | β | 2016 | β |
| Induced pluripotent stem cells for modeling and cell therapy of Parkinson's disease. | CsΓΆbΓΆnyeiovΓ‘ M et al. | β | 2016 | β |
| Intrastriatal Grafting of Chromospheres: Survival and Functional Effects in the 6-OHDA Rat Model of Parkinson's Disease. | Boronat-GarcΓa A et al. | β | 2016 | β |
| LIN28A enhances the therapeutic potential of cultured neural stem cells in a Parkinson's disease model. | Rhee YH et al. | β | 2016 | β |
| Midbrain-like Organoids from Human Pluripotent Stem Cells Contain Functional Dopaminergic and Neuromelanin-Producing Neurons. | Jo J et al. | β | 2016 | β |
| Molecular Diversity of Midbrain Development in Mouse, Human, and Stem Cells. | La Manno G et al. | β | 2016 | β |
| Molecular Features Underlying Neurodegeneration Identified through InΒ Vitro Modeling of Genetically Diverse Parkinson's Disease Patients. | Lin L et al. | β | 2016 | β |
| N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data. | Monti DA et al. | β | 2016 | β |
| Neural Stem Cells Derived from Human Parthenogenetic Stem Cells Engraft and Promote Recovery in a Nonhuman Primate Model of Parkinson's Disease. | Gonzalez R et al. | β | 2016 | β |
| Neural Subtype Specification from Human Pluripotent Stem Cells. | Tao Y et al. | β | 2016 | β |
| Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. | Sarkar S et al. | β | 2016 | β |
| Nonhuman primate model in clinical modeling of diseases for stem cell therapy. | Choudhury GR et al. | β | 2016 | β |
| Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and Ξ±-Synuclein Accumulation. | Chung SY et al. | β | 2016 | β |
| Plasmid-Based Generation of Induced Neural Stem Cells from Adult Human Fibroblasts. | Capetian P et al. | β | 2016 | β |
| Pluripotent stem cells: the last 10 years. | Kimbrel EA et al. | β | 2016 | β |
| Purification of functional human ES and iPSC-derived midbrain dopaminergic progenitors using LRTM1. | Samata B et al. | β | 2016 | β |
| Role of sulfiredoxin as a peroxiredoxin-2 denitrosylase in human iPSC-derived dopaminergic neurons. | Sunico CR et al. | β | 2016 | β |
| Semaphorin 3C Released from a Biocompatible Hydrogel Guides and Promotes Axonal Growth of Rodent and Human Dopaminergic Neurons. | Carballo-Molina OA et al. | β | 2016 | β |
| Stem Cell-Mediated Regeneration of the Adult Brain. | Jessberger S | β | 2016 | β |
| Stem Cell Therapy: A Prospective Treatment for Alzheimer's Disease. | Lee JH et al. | β | 2016 | β |
| Substrate Stiffness Modulates the Maturation of Human Pluripotent Stem-Cell-Derived Hepatocytes. | Mittal N et al. | β | 2016 | β |
| Synthetic Morphogenesis. | Teague BP et al. | β | 2016 | β |
| Targeted Differentiation of Regional Ventral Neuroprogenitors and Related Neuronal Subtypes from Human Pluripotent Stem Cells. | Chi L et al. | β | 2016 | β |
| The Preclinical Research Progress of Stem Cells Therapy in Parkinson's Disease. | Zhang J et al. | β | 2016 | β |
| Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis. | Farzanehfar P | β | 2016 | β |
| Using iPSC-derived human DA neurons from opioid-dependent subjects to study dopamine dynamics. | Sheng Y et al. | β | 2016 | β |
| Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders. | Barral S et al. | β | 2016 | β |